Phenotypes associated with this allele

• Allele Symbol: Tg(Pbsn-cre)4Prb
• Allele Name: transgene insertion 4, Pradip Roy-Burman
• Allele ID: MGI:2385927
• Summary: 72 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Eaf1^tm1.1Zhow/Eaf1^tm1.1Zhow Tg(Pbsn-cre)4Prb/0	B6(Cg)-Eaf1^tm1.1Zhow Tg(Pbsn-cre)4Prb	MGI:6694948
cn2	Cop1^tm2.1Vmd/Cop1^+ Tg(Pbsn-cre)4Prb/0	B6N.CgCop1^tm2.1Vmd Pten^tm1Hwu Tg(Pbsn-cre)4Prb	MGI:5013603
cn3	Pten^tm1Hwu/Pten^tm1Hwu Cop1^tm2.1Vmd/Cop1^tm2.1Vmd Tg(Pbsn-cre)4Prb/0	B6N.CgCop1^tm2.1Vmd Pten^tm1Hwu Tg(Pbsn-cre)4Prb	MGI:5013604
cn4	Cop1^tm2.1Vmd/Cop1^tm2.1Vmd Tg(Pbsn-cre)4Prb/0	B6N.Cg-Cop1^tm2.1Vmd Tg(Pbsn-cre)4Prb	MGI:5013605
cn5	Cop1^tm2.1Vmd/Cop1^+ Tg(Pbsn-cre)4Prb/0	B6N.Cg-Cop1^tm2.1Vmd Tg(Pbsn-cre)4Prb	MGI:5013606
cn6	Gt(ROSA)26Sor^tm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor^+ Pten^tm2.1Ppp/Pten^tm2.1Ppp Rb1^tm2Brn/Rb1^+ Tg(Pbsn-cre)4Prb/0	involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:7277820
cn7	Gt(ROSA)26Sor^tm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor^+ Pten^tm2.1Ppp/Pten^tm2.1Ppp Rb1^tm2Brn/Rb1^tm2Brn Tg(Pbsn-cre)4Prb/0	involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:7277819
cn8	Gt(ROSA)26Sor^tm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor^+ Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb/0	involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:7277821
cn9	Pten^tm2.1Ppp/Pten^tm2.1Ppp Rb1^tm2Brn/Rb1^tm2Brn Tg(Pbsn-cre)4Prb/0	involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:7277828
cn10	Hspa5^tm1Alee/Hspa5^tm1.1Alee Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/?	involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2	MGI:4943512
cn11	Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2	MGI:3805865
cn12	Hspa5^tm1Alee/Hspa5^tm1Alee Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/?	involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2	MGI:4943513
cn13	Hspa5^tm1Alee/Hspa5^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/?	involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2	MGI:4943514
cn14	Gt(ROSA)26Sor^tm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sor^+ Tg(Pbsn-cre)4Prb/0	involves: 129 * C57BL/6 * DBA/2	MGI:5524278
cn15	Pik3cb^tm1Jjz/Pik3cb^tm1Jjz Tg(Pbsn-cre)4Prb/0	involves: 129 * C57BL/6 * DBA/2	MGI:3805861
cn16	Pik3ca^tm1Jjz/Pik3ca^tm1Jjz Tg(Pbsn-cre)4Prb/0	involves: 129 * C57BL/6 * DBA/2	MGI:3805864
cn17	Pten^tm1Rdp/Pten^tm1Rdp Smad4^tm1Rdp/Smad4^tm1Rdp Trp53^tm1Brn/Trp53^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129 * C57BL/6 * DBA/2	MGI:5431947
cn18	Gt(ROSA)26Sor^tm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sor^tm1(TMPRSS2/ERG)Key Tg(Pbsn-cre)4Prb/0	involves: 129 * C57BL/6 * DBA/2	MGI:5524279
cn19	Hspa5^tm1Alee/Hspa5^tm1Alee Tg(Pbsn-cre)4Prb/0	involves: 129 * C57BL/6 * DBA/2	MGI:4943515
cn20	Igs2^tm1(CAG-Met)Zsu/Igs2^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129 * C57BL/6 * DBA/2 * FVB/N	MGI:6507866
cn21	Pten^tm1Rdp/Pten^tm1Rdp Tert^tm1Rdp/Tert^+ Trp53^tm1Brn/Trp53^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:5431944
cn22	Pten^tm1Rdp/Pten^tm1Rdp Tert^tm1Rdp/Tert^tm1Rdp Trp53^tm1Brn/Trp53^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:5431943
cn23	Pten^tm1Rdp/Pten^tm1Rdp Tert^tm3Rdp/Tert^tm3Rdp Trp53^tm1Brn/Trp53^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:5431978
cn24	Pten^tm1Rdp/Pten^tm1Rdp Trp53^tm1Brn/Trp53^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2	MGI:5431945
cn25	Eaf1^tm1.1Zhow/Eaf1^tm1.1Zhow Eaf2^tm1Zhow/Eaf2^tm1Zhow Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2	MGI:6694954
cn26	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53^+ Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4819194
cn27	Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4819193
cn28	Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4819192
cn29	Gt(ROSA)26Sor^tm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor^+ Pten^tm1Mro/Pten^+ Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N	MGI:5427498
cn30	Gt(ROSA)26Sor^tm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor^+ Tg(Pbsn-cre)4Prb/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N	MGI:5427497
cn31	Col1a1^tm1(tetO-YAP1*)Fcam/Col1a1^+ Gt(ROSA)26Sor^tm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2	MGI:5705651
cn32	Ar^tm1Verh/Y Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2	MGI:5009703
cn33	Kras^tm1Bbd/Kras^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2	MGI:3836577
cn34	Gt(ROSA)26Sor^tm1(CAG-PTPN1,-EGFP)Mtr/Gt(ROSA)26Sor^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2	MGI:6378625
cn35	Eif4e^tm1.1Lfur/Eif4e^tm1.1Lfur Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2	MGI:4830313
cn36	Ctnnb1^tm1Mmt/Ctnnb1^+ Kras^tm1Bbd/Kras^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2	MGI:3836578
cn37	Ctnnb1^tm1Mmt/Ctnnb1^+ Igs2^tm1(CAG-Met)Zsu/Igs2^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N	MGI:6507888
cn38	Igs2^tm1(CAG-Met)Zsu/Igs2^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N	MGI:6507865
cn39	Gt(ROSA)26Sor^tm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor^+ Pten^tm2.1Ppp/Pten^+ Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * C57BL/6 * DBA/2	MGI:6275174
cn40	Pten^tm2.1Ppp/Pten^tm2.1Ppp Trp53^tm1Thl/Trp53^tm1Thl Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * C57BL/6 * DBA/2	MGI:3603330
cn41	Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * C57BL/6 * DBA/2	MGI:2679901
cn42	Gt(ROSA)26Sor^tm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sor^tm1(TMPRSS2/ERG)Key Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * C57BL/6 * DBA/2	MGI:5524280
cn43	Gt(ROSA)26Sor^tm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor^+ Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb/0	involves: 129S1/Sv * C57BL/6 * DBA/2	MGI:6275175
cn44	Eif2ak3^tm1.2Drc/Eif2ak3^tm1.2Drc Pten^tm1Hwu/Pten^tm1Hwu Tg(CAG-MYC,-GFP*)#Rugg/0 Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2	MGI:6198768
cn45	Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2	MGI:4420974
cn46	Pten^tm1Hwu/Pten^tm1Hwu Tg(CAG-fat-1)1Jxk/0 Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2	MGI:4847617
cn47	Pten^tm1Hwu/Pten^+ Tg(ARR2/Pbsn-FGF8)3Prb/0 Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2	MGI:4843916
cn48	Pten^tm1Hwu/Pten^+ Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2	MGI:4420975
cn49	Pten^tm1Hwu/Pten^tm1Hwu Tg(CAG-MYC,-GFP*)#Rugg/0 Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2	MGI:6198766
cn50	Apc^tm1Tno/Apc^tm1Tno Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2	MGI:5566610
cn51	Pten^tm1Hwu/Pten^+ Tmprss2^tm2.1(ETV1)Sho/Tmprss2^tm2.1(ETV1)Sho Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:5578649
cn52	Erg^tm1.1Sho/Erg^tm1.1Sho Pten^tm1Hwu/Pten^tm1Hwu Tmprss2^tm3Sho/Tmprss2^tm3Sho Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:5578652
cn53	Rxra^tm1Krc/Rxra^+ Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:2449982
cn54	Kras^tm4Tyj/Kras^+ Pten^tm1Hwu/Pten^+ Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:5705328
cn55	Kras^tm4Tyj/Kras^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:5705321
cn56	Rxra^tm1Krc/Rxra^tm1Krc Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:2449983
cn57	Gt(ROSA)26Sor^tm2(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:5008589
cn58	Gt(ROSA)26Sor^tm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor^+ Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:5008586
cn59	Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:4358249
cn60	Pten^tm1Hwu/Pten^tm1Hwu Ptpn1^tm1Bpk/Ptpn1^tm1Bpk Tg(Pbsn-cre)4Prb/0	involves: 129S4/SvJae * C57BL/6 * DBA/2	MGI:6378626
cn61	Zfhx3^tm1.1Jtd/Zfhx3^tm1.1Jtd Tg(Pbsn-cre)4Prb/0	involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL	MGI:5446522
cn62	Ar^tm1Chc/Y Tg(Pbsn-cre)4Prb/0	involves: 129S/SvEv * C57BL/6 * DBA/2	MGI:3773634
cn63	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/? Tg(Pbsn-cre)4Prb/?	involves: 129X1/SvJ * C57BL/6 * DBA/2	MGI:3716207
cn64	Ctnnb1^tm1Mmt/Ctnnb1^+ Tg(Pbsn-cre)4Prb/0	involves: 129X1/SvJ * C57BL/6 * DBA/2	MGI:3836579
cn65	Tg(CAG-MYC,-GFP*)#Rugg/0 Tg(Pbsn-cre)4Prb/0	involves: C57BL/6 * C57BL/6J * DBA/2	MGI:6198765
cn66	Klf5^tm1.1Jtd/Klf5^+ Tg(Pbsn-cre)4Prb/0	involves: C57BL/6 * DBA/2	MGI:5551716
cn67	Klf5^tm1.1Jtd/Klf5^tm1.1Jtd Tg(Pbsn-cre)4Prb/0	involves: C57BL/6 * DBA/2	MGI:5551715
cn68	Tg(CAG-cat,-ALOX15)1868Klv/0 Tg(Pbsn-cre)4Prb/0	involves: C57BL/6 * DBA/2	MGI:6114993
cn69	Tg(CAG-cat,-ALOX15)1868Klv/Tg(CAG-cat,-ALOX15)1868Klv Tg(Pbsn-cre)4Prb/?	involves: C57BL/6 * DBA/2	MGI:6114995
cn70	Pten^tm1Mro/Pten^+ Tg(Pbsn-cre)4Prb/0	involves: C57BL/6 * DBA/2	MGI:5427499
cn71	Gt(ROSA)26Sor^tm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor^+ Tg(Pbsn-cre)4Prb/0	involves: C57BL/6 * DBA/2	MGI:6275172
cn72	Trp53^tm1Thl/Trp53^tm1Thl Tg(Pbsn-cre)4Prb/0	involves: C57BL/6 * DBA/2	MGI:3603329

Genotype
MGI:6694948

cn1

• Allelic Composition: Eaf1^tm1.1Zhow/Eaf1^tm1.1Zhow; Tg(Pbsn-cre)4Prb/0
• Genetic Background: B6(Cg)-Eaf1^tm1.1Zhow Tg(Pbsn-cre)4Prb

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:288972 )

♂ • mouse prostatic intraepithelial neoplasia (mPIN) lesions

abnormal prostate gland physiology ( J:288972 )

♂ • increased epithelial cell proliferation in ventral prostate

prostate gland inflammation ( J:288972 )

♂ • stroma inflammation

♂ • increased CD3+ T cell and CD19+ B cell infiltration of ventral prostate

immune system

prostate gland inflammation ( J:288972 )

♂ • stroma inflammation

♂ • increased CD3+ T cell and CD19+ B cell infiltration of ventral prostate

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:288972 )

♂ • mouse prostatic intraepithelial neoplasia (mPIN) lesions

reproductive system

reproductive system phenotype ( J:288972 )

♂N • fertile

increased prostate intraepithelial neoplasia incidence ( J:288972 )

♂ • mouse prostatic intraepithelial neoplasia (mPIN) lesions

abnormal prostate gland physiology ( J:288972 )

♂ • increased epithelial cell proliferation in ventral prostate

prostate gland inflammation ( J:288972 )

♂ • stroma inflammation

♂ • increased CD3+ T cell and CD19+ B cell infiltration of ventral prostate

Genotype
MGI:5013603

cn2

• Allelic Composition: Cop1^tm2.1Vmd/Cop1⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: B6N.CgCop1^tm2.1Vmd Pten^tm1Hwu Tg(Pbsn-cre)4Prb

neoplasm

increased prostate gland adenocarcinoma incidence ( J:172653 )

♂ • invasive in 1 of 6 mice at 30 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • high grade in 5 of 6 mice at 30 weeks of age

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:172653 )

♂ • invasive in 1 of 6 mice at 30 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • high grade in 5 of 6 mice at 30 weeks of age

reproductive system

increased prostate gland adenocarcinoma incidence ( J:172653 )

♂ • invasive in 1 of 6 mice at 30 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • high grade in 5 of 6 mice at 30 weeks of age

Genotype
MGI:5013604

cn3

• Allelic Composition: Pten^tm1Hwu/Pten^tm1Hwu; Cop1^tm2.1Vmd/Cop1^tm2.1Vmd; Tg(Pbsn-cre)4Prb/0
• Genetic Background: B6N.CgCop1^tm2.1Vmd Pten^tm1Hwu Tg(Pbsn-cre)4Prb

neoplasm

increased prostate gland adenocarcinoma incidence ( J:172653 )

♂ • invasive in 11 of 13 mice at 30 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • high grade in 2 of 13 mice at 30 weeks of age

reproductive system

increased prostate gland adenocarcinoma incidence ( J:172653 )

♂ • invasive in 11 of 13 mice at 30 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • high grade in 2 of 13 mice at 30 weeks of age

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:172653 )

♂ • invasive in 11 of 13 mice at 30 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • high grade in 2 of 13 mice at 30 weeks of age

Genotype
MGI:5013605

cn4

• Allelic Composition: Cop1^tm2.1Vmd/Cop1^tm2.1Vmd; Tg(Pbsn-cre)4Prb/0
• Genetic Background: B6N.Cg-Cop1^tm2.1Vmd Tg(Pbsn-cre)4Prb

reproductive system

prostate gland hyperplasia ( J:172653 )

♂ • in 3 of 4 mice at 40 weeks of age

♂ • in all mice at 52 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • low grade in 2 of 6 mice at 52 weeks of age

abnormal prostate gland physiology ( J:172653 )

♂ • cells in the ventral and lateral prostate exhibit increased proliferation compared to in wild-type mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • low grade in 2 of 6 mice at 52 weeks of age

endocrine/exocrine glands

prostate gland hyperplasia ( J:172653 )

♂ • in 3 of 4 mice at 40 weeks of age

♂ • in all mice at 52 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:172653 )

♂ • low grade in 2 of 6 mice at 52 weeks of age

abnormal prostate gland physiology ( J:172653 )

♂ • cells in the ventral and lateral prostate exhibit increased proliferation compared to in wild-type mice

Genotype
MGI:5013606

cn5

• Allelic Composition: Cop1^tm2.1Vmd/Cop1⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: B6N.Cg-Cop1^tm2.1Vmd Tg(Pbsn-cre)4Prb

reproductive system

prostate gland hyperplasia ( J:172653 )

♂ • in 1 of 7 mice at 52 weeks of age

endocrine/exocrine glands

prostate gland hyperplasia ( J:172653 )

♂ • in 1 of 7 mice at 52 weeks of age

Genotype
MGI:7277820

cn6

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-MYCN,-luc)Jhsc}/Gt(ROSA)26Sor⁺; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Rb1^tm2Brn/Rb1⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2

mortality/aging

premature death ( J:307910 )

♂ • median survival time of 19 weeks

neoplasm

increased prostate gland tumor incidence ( J:307910 )

♂ • mice develop large, invasive tumors with androgen receptor (AR)-negative and poorly differentiated foci as early as 12 weeks

♂ • these regions show little resemblance to conventional adenocarcinoma but are negative for neuroendocrine markers, potentially as a transition between conventional adenocarcinoma and neuroendocrine prostate cancer (NEPC) states

♂ • some foci are positive for neuroendocrine markers INSM1, EZH2, and NKX2-1 and some foci display condensed nuclei and scant cytoplasm, characteristic of NEPC morphology

♂ • tumors also include other foci of divergent differentiation like intestinal and squamous, as well as conventional, AR+ adenocarcinoma, but the percentage of conventional adenocarcinoma decreases over time while the percentage of poorly differentiated histology increases over time

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:307910 )

♂ • mice develop large, invasive tumors with androgen receptor (AR)-negative and poorly differentiated foci as early as 12 weeks

♂ • these regions show little resemblance to conventional adenocarcinoma but are negative for neuroendocrine markers, potentially as a transition between conventional adenocarcinoma and neuroendocrine prostate cancer (NEPC) states

♂ • some foci are positive for neuroendocrine markers INSM1, EZH2, and NKX2-1 and some foci display condensed nuclei and scant cytoplasm, characteristic of NEPC morphology

♂ • tumors also include other foci of divergent differentiation like intestinal and squamous, as well as conventional, AR+ adenocarcinoma, but the percentage of conventional adenocarcinoma decreases over time while the percentage of poorly differentiated histology increases over time

reproductive system

increased prostate gland tumor incidence ( J:307910 )

♂ • mice develop large, invasive tumors with androgen receptor (AR)-negative and poorly differentiated foci as early as 12 weeks

♂ • these regions show little resemblance to conventional adenocarcinoma but are negative for neuroendocrine markers, potentially as a transition between conventional adenocarcinoma and neuroendocrine prostate cancer (NEPC) states

♂ • some foci are positive for neuroendocrine markers INSM1, EZH2, and NKX2-1 and some foci display condensed nuclei and scant cytoplasm, characteristic of NEPC morphology

♂ • tumors also include other foci of divergent differentiation like intestinal and squamous, as well as conventional, AR+ adenocarcinoma, but the percentage of conventional adenocarcinoma decreases over time while the percentage of poorly differentiated histology increases over time

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate neuroendocrine neoplasm		DOID:2992		J:307910

Genotype
MGI:7277819

cn7

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-MYCN,-luc)Jhsc}/Gt(ROSA)26Sor⁺; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Rb1^tm2Brn/Rb1^tm2Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2

mortality/aging

premature death ( J:307910 )

♂ • median survival time of 12.5 weeks

♂ • castrated mice have a median survival time of 24 weeks

neoplasm

increased prostate gland tumor incidence ( J:307910 )

♂ • mice develop large, invasive prostate tumors with androgen receptor (AR)-negative and poorly differentiated foci as early as 8 weeks

♂ • these regions show little resemblance to conventional adenocarcinoma but are negative for neuroendocrine markers, potentially as a transition between conventional adenocarcinoma and neuroendocrine prostate cancer (NEPC) states

♂ • some foci are positive for neuroendocrine markers INSM1, EZH2, and NKX2-1 and some foci display condensed nuclei and scant cytoplasm, characteristic of NEPC morphology

♂ • tumors also include other foci of divergent differentiation like intestinal and squamous, as well as conventional, AR+ adenocarcinoma, but the percentage of conventional adenocarcinoma decreases over time while the percentage of poorly differentiated histology increases over time

♂ • mice do not respond to surgical castration and continue to grow tumors rapidly

♂ • post-castration tumors harbor foci enriched with divergent differentiated histology compared to adenocarcinoma and increased metastatic potential

increased metastatic potential ( J:307910 )

♂ • onset of metastasis occurs as early as 8 weeks and by 12 weeks, 100% of mice develop distant metastatic lesions; metastases to the lung, liver, lymph nodes, and kidney primarily consist of large and small cell neuroendocrine histologies that are AR-negative

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:307910 )

♂ • mice develop large, invasive prostate tumors with androgen receptor (AR)-negative and poorly differentiated foci as early as 8 weeks

♂ • these regions show little resemblance to conventional adenocarcinoma but are negative for neuroendocrine markers, potentially as a transition between conventional adenocarcinoma and neuroendocrine prostate cancer (NEPC) states

♂ • some foci are positive for neuroendocrine markers INSM1, EZH2, and NKX2-1 and some foci display condensed nuclei and scant cytoplasm, characteristic of NEPC morphology

♂ • tumors also include other foci of divergent differentiation like intestinal and squamous, as well as conventional, AR+ adenocarcinoma, but the percentage of conventional adenocarcinoma decreases over time while the percentage of poorly differentiated histology increases over time

♂ • mice do not respond to surgical castration and continue to grow tumors rapidly

♂ • post-castration tumors harbor foci enriched with divergent differentiated histology compared to adenocarcinoma and increased metastatic potential

reproductive system

increased prostate gland tumor incidence ( J:307910 )

♂ • mice develop large, invasive prostate tumors with androgen receptor (AR)-negative and poorly differentiated foci as early as 8 weeks

♂ • these regions show little resemblance to conventional adenocarcinoma but are negative for neuroendocrine markers, potentially as a transition between conventional adenocarcinoma and neuroendocrine prostate cancer (NEPC) states

♂ • some foci are positive for neuroendocrine markers INSM1, EZH2, and NKX2-1 and some foci display condensed nuclei and scant cytoplasm, characteristic of NEPC morphology

♂ • tumors also include other foci of divergent differentiation like intestinal and squamous, as well as conventional, AR+ adenocarcinoma, but the percentage of conventional adenocarcinoma decreases over time while the percentage of poorly differentiated histology increases over time

♂ • mice do not respond to surgical castration and continue to grow tumors rapidly

♂ • post-castration tumors harbor foci enriched with divergent differentiated histology compared to adenocarcinoma and increased metastatic potential

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate neuroendocrine neoplasm		DOID:2992		J:307910

Genotype
MGI:7277821

cn8

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-MYCN,-luc)Jhsc}/Gt(ROSA)26Sor⁺; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2

mortality/aging

premature death ( J:307910 )

♂ • median survival time of 26 weeks

♂ • castrated mice have a median survival time of 44 weeks

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:307910 )

♂ • mice develop prostate tumors that have primarily high-grade prostatic intraepithelial neoplasia at earlier time points

♂ • tumors regress post-castration but resume growth 24 weeks post-castration

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:307910 )

♂ • mice develop prostate tumors that have primarily high-grade prostatic intraepithelial neoplasia at earlier time points

♂ • tumors regress post-castration but resume growth 24 weeks post-castration

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:307910 )

♂ • mice develop prostate tumors that have primarily high-grade prostatic intraepithelial neoplasia at earlier time points

♂ • tumors regress post-castration but resume growth 24 weeks post-castration

Genotype
MGI:7277828

cn9

• Allelic Composition: Pten^tm2.1Ppp/Pten^tm2.1Ppp; Rb1^tm2Brn/Rb1^tm2Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2

mortality/aging

premature death ( J:307910 )

• median survival time of 38 weeks

• castrated mice have a median survival time of 43.5 weeks

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:307910 )

• prostates from 8-week-old mice are composed of androgen receptor-positive, high-grade prostatic intraepithelial neoplasia lesions

• tumors regress post-castration but resume growth 24 weeks post-castration

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:307910 )

• prostates from 8-week-old mice are composed of androgen receptor-positive, high-grade prostatic intraepithelial neoplasia lesions

• tumors regress post-castration but resume growth 24 weeks post-castration

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:307910 )

• prostates from 8-week-old mice are composed of androgen receptor-positive, high-grade prostatic intraepithelial neoplasia lesions

• tumors regress post-castration but resume growth 24 weeks post-castration

Genotype
MGI:4943512

cn10

• Allelic Composition: Hspa5^tm1Alee/Hspa5^tm1.1Alee; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/?
• Genetic Background: involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2

neoplasm

neoplasm ( J:142106 )

N • mice do not develop detectable cancerous or precancerous lesions in the prostate

Genotype
MGI:3805865

cn11

• Allelic Composition: Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2

neoplasm

increased prostate gland tumor incidence ( J:142106 )

♂ • mutants develop tumors between 12 to 20 weeks, with 100% penetrance at 20 weeks

increased prostate gland adenocarcinoma incidence ( J:142106 )

♂ • all mice develop invasive adenocarcinoma in all prostate lobes

♂ • malignant cells invade through the basement membrane into the adjacent stroma, inducing both an inflammatory and a desmoplastic response, resulting in growth of fibrous and connective tissue around the tumor

increased prostate intraepithelial neoplasia incidence ( J:138565 )

♂ • mice develop prostate intraepithelial neoplasias

reproductive system

increased prostate gland tumor incidence ( J:142106 )

♂ • mutants develop tumors between 12 to 20 weeks, with 100% penetrance at 20 weeks

increased prostate gland adenocarcinoma incidence ( J:142106 )

♂ • all mice develop invasive adenocarcinoma in all prostate lobes

♂ • malignant cells invade through the basement membrane into the adjacent stroma, inducing both an inflammatory and a desmoplastic response, resulting in growth of fibrous and connective tissue around the tumor

increased prostate intraepithelial neoplasia incidence ( J:138565 )

♂ • mice develop prostate intraepithelial neoplasias

female infertility ( J:142106 )

♀

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:142106 )

♂ • mutants develop tumors between 12 to 20 weeks, with 100% penetrance at 20 weeks

increased prostate gland adenocarcinoma incidence ( J:142106 )

♂ • all mice develop invasive adenocarcinoma in all prostate lobes

♂ • malignant cells invade through the basement membrane into the adjacent stroma, inducing both an inflammatory and a desmoplastic response, resulting in growth of fibrous and connective tissue around the tumor

increased prostate intraepithelial neoplasia incidence ( J:138565 )

♂ • mice develop prostate intraepithelial neoplasias

Genotype
MGI:4943513

cn12

• Allelic Composition: Hspa5^tm1Alee/Hspa5^tm1Alee; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/?
• Genetic Background: involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2

neoplasm

neoplasm ( J:142106 )

N • mice do not develop detectable cancerous or precancerous lesions in the prostate

Genotype
MGI:4943514

cn13

• Allelic Composition: Hspa5^tm1Alee/Hspa5⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/?
• Genetic Background: involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2

neoplasm

increased prostate gland adenocarcinoma incidence ( J:142106 )

♂ • mutants exhibit visible solid tumor mass with invasive adenocarcinoma in the anterior prostate, while the dorsolateral prostate and ventral prostate lobes keep their ductual structure, albeit with enlarged ducts

increased prostate intraepithelial neoplasia incidence ( J:142106 )

♂ • dorsolateral prostate and ventral prostate exhibit diffusive prostate intraepithelial neoplasia (PIN) with intact basement membrane

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:142106 )

♂ • mutants exhibit visible solid tumor mass with invasive adenocarcinoma in the anterior prostate, while the dorsolateral prostate and ventral prostate lobes keep their ductual structure, albeit with enlarged ducts

increased prostate intraepithelial neoplasia incidence ( J:142106 )

♂ • dorsolateral prostate and ventral prostate exhibit diffusive prostate intraepithelial neoplasia (PIN) with intact basement membrane

reproductive system

increased prostate gland adenocarcinoma incidence ( J:142106 )

♂ • mutants exhibit visible solid tumor mass with invasive adenocarcinoma in the anterior prostate, while the dorsolateral prostate and ventral prostate lobes keep their ductual structure, albeit with enlarged ducts

increased prostate intraepithelial neoplasia incidence ( J:142106 )

♂ • dorsolateral prostate and ventral prostate exhibit diffusive prostate intraepithelial neoplasia (PIN) with intact basement membrane

Genotype
MGI:5524278

cn14

• Allelic Composition: Gt(ROSA)26Sor^{tm1(TMPRSS2/ERG)Key}/Gt(ROSA)26Sor⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * C57BL/6 * DBA/2

reproductive system

prostate gland ventral lobe hyperplasia ( J:200002 )

♂ • focal ventral lobe hyperplasia after 1 year of age in 50% of mice

endocrine/exocrine glands

prostate gland ventral lobe hyperplasia ( J:200002 )

♂ • focal ventral lobe hyperplasia after 1 year of age in 50% of mice

Genotype
MGI:3805861

cn15

• Allelic Composition: Pik3cb^tm1Jjz/Pik3cb^tm1Jjz; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * C57BL/6 * DBA/2

neoplasm

neoplasm ( J:138565 )

N • unlike in Pten null mice, tumorigenesis in the prostate is not detected

Genotype
MGI:3805864

cn16

• Allelic Composition: Pik3ca^tm1Jjz/Pik3ca^tm1Jjz; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * C57BL/6 * DBA/2

cellular

abnormal cell physiology ( J:138565 )

• following cre-mediated recombination, mouse embryonic fibroblasts (MEFs) undergo reduced levels of immortalization upon exposure to HRas-G12V or EGFR-Del from feeder cells

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:138565 )

♂ • mice develop prostate intraepithelial neoplasias

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:138565 )

♂ • mice develop prostate intraepithelial neoplasias

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:138565 )

♂ • mice develop prostate intraepithelial neoplasias

Genotype
MGI:5431947

cn17

• Allelic Composition: Pten^tm1Rdp/Pten^tm1Rdp; Smad4^tm1Rdp/Smad4^tm1Rdp; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * C57BL/6 * DBA/2

mortality/aging

premature death ( J:186105 )

• survival time is shorter than in mutant mice wild-type for Smad4

• median survival time of 17.05 weeks

neoplasm

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

♂ • tumors are more aggressive than in mutant mice wild-type for Smad4

increased metastatic potential ( J:186105 )

• bone metastases are seen in some (3 of 24) mice unlike in mutant mice wild-type for Smad4

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

♂ • tumors are more aggressive than in mutant mice wild-type for Smad4

reproductive system

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

♂ • tumors are more aggressive than in mutant mice wild-type for Smad4

Genotype
MGI:5524279

cn18

• Allelic Composition: Gt(ROSA)26Sor^{tm1(TMPRSS2/ERG)Key}/Gt(ROSA)26Sor^{tm1(TMPRSS2/ERG)Key}; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * C57BL/6 * DBA/2

reproductive system

prostate gland ventral lobe hyperplasia ( J:200002 )

♂ • focal ventral lobe hyperplasia after 1 year of age in 50% of mice

endocrine/exocrine glands

prostate gland ventral lobe hyperplasia ( J:200002 )

♂ • focal ventral lobe hyperplasia after 1 year of age in 50% of mice

Genotype
MGI:4943515

cn19

• Allelic Composition: Hspa5^tm1Alee/Hspa5^tm1Alee; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * C57BL/6 * DBA/2

reproductive system

reproductive system phenotype ( J:142106 )

N • mice are phenotypically normal and fertile and prostate morphology is normal

Genotype
MGI:6507866

cn20

• Allelic Composition: Igs2^{tm1(CAG-Met)Zsu}/Igs2⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129 * C57BL/6 * DBA/2 * FVB/N

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:268934 )

♂ • mice develop prostatic sarcomatoid carcinoma

♂ • mice show a more aggressive prostatic tumor phenotype than single conditional Pten^tm1Hwu mice

increased prostate gland adenocarcinoma incidence ( J:268934 )

♂ • mice develop prostatic adenocarcinomas and invasive carcinomas

increased prostate intraepithelial neoplasia incidence ( J:268934 )

♂ • 5 of 5 mice develop multifocal high grade intraepithelial neoplasia (PIN) before 4 months of age

neoplasm

increased prostate gland tumor incidence ( J:268934 )

♂ • mice develop prostatic sarcomatoid carcinoma

♂ • mice show a more aggressive prostatic tumor phenotype than single conditional Pten^tm1Hwu mice

increased prostate gland adenocarcinoma incidence ( J:268934 )

♂ • mice develop prostatic adenocarcinomas and invasive carcinomas

increased prostate intraepithelial neoplasia incidence ( J:268934 )

♂ • 5 of 5 mice develop multifocal high grade intraepithelial neoplasia (PIN) before 4 months of age

increased metastatic potential ( J:268934 )

♂ • prostate cancer metastasis after 10 months of age with 62.5% of mice showing metastatic lesions

♂ • metastasis to lungs and periprostatic lymph nodes is seen

♂ • mice show an overall more invasive tumor phenotype than single conditional Pten^tm1Hwu mice

increased carcinoma incidence ( J:268934 )

♂ • 1 of 5 mice show invasive pancreatic carcinoma at 4-10 months and 6 of 8 mice develop invasive carcinoma after 10 months of age; 5 of 8 mice have invasive carcinoma with epithelial-mesenchymal transition and 5 of 8 mice have invasive carcinoma with metastasis

♂ • mice exhibit a transition from prostatic adenocarcinoma and invasive carcinoma lesions to pathology resembling prostatic sarcamoid carcinomas

♂ • sarcamoid carcinomas show spindle-like tumor cells, tumor cells with a multitude of mitotic figures, and haphazard acini and lobules of pleomorphic cells, indicating that these lesions possess mesenchymal morphology and proliferative and invasive features

reproductive system

increased prostate gland tumor incidence ( J:268934 )

♂ • mice develop prostatic sarcomatoid carcinoma

♂ • mice show a more aggressive prostatic tumor phenotype than single conditional Pten^tm1Hwu mice

increased prostate gland adenocarcinoma incidence ( J:268934 )

♂ • mice develop prostatic adenocarcinomas and invasive carcinomas

increased prostate intraepithelial neoplasia incidence ( J:268934 )

♂ • 5 of 5 mice develop multifocal high grade intraepithelial neoplasia (PIN) before 4 months of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:268934

Genotype
MGI:5431944

cn21

• Allelic Composition: Pten^tm1Rdp/Pten^tm1Rdp; Tert^tm1Rdp/Tert⁺; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2

mortality/aging

premature death ( J:186105 )

neoplasm

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

reproductive system

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

Genotype
MGI:5431943

cn22

• Allelic Composition: Pten^tm1Rdp/Pten^tm1Rdp; Tert^tm1Rdp/Tert^tm1Rdp; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • at generations 3 and 4 (G3/4), all mice develop smaller, poorly progressive tumors compared to G0 mice

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

♂ • most tumors fail to progress beyond HPIN by 24 weeks of age unlike in G0 mice

decreased tumor growth/size ( J:186105 )

• smaller, poorly progressive tumors compared to tumors in G0 mice

• markedly increased apoptosis and decreased proliferation in tumor cells compared tumor cells from G0 mice

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • at generations 3 and 4 (G3/4), all mice develop smaller, poorly progressive tumors compared to G0 mice

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

♂ • most tumors fail to progress beyond HPIN by 24 weeks of age unlike in G0 mice

cellular

decreased telomere length ( J:186105 )

• reduced at G3/4

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • at generations 3 and 4 (G3/4), all mice develop smaller, poorly progressive tumors compared to G0 mice

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

♂ • most tumors fail to progress beyond HPIN by 24 weeks of age unlike in G0 mice

Genotype
MGI:5431978

cn23

• Allelic Composition: Pten^tm1Rdp/Pten^tm1Rdp; Tert^tm3Rdp/Tert^tm3Rdp; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2

mortality/aging

decreased tumor-free survival time ( J:186105 )

• develop bulky lethal tumors by age 24 weeks of age

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • at generations 3 and 4 (G3/4), all develop invasive prostate adenocarcinomas by 24 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • at G3/4, high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

neoplasm

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • at generations 3 and 4 (G3/4), all develop invasive prostate adenocarcinomas by 24 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • at G3/4, high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

increased metastatic potential ( J:186105 )

• in some (5 of 20) G3/4 mice lumbar spine metastases are seen unlike in G0 mice

reproductive system

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • at generations 3 and 4 (G3/4), all develop invasive prostate adenocarcinomas by 24 weeks of age

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • at G3/4, high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

cellular

abnormal chromosome morphology ( J:186105 )

• increase in the number of chromosomal aberrations in tumor cells from G3/4 mice compared to G0 mice

increased telomere length ( J:186105 )

• increased length in prostate tumor cells compared to G3/4 mice homozygous for Tert^tm1Rdp, Pten^tm1Rdp and Trp53^tm1Brn and hemizygous for Tg(Pbsn-cre)4Prb

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:186105

Genotype
MGI:5431945

cn24

• Allelic Composition: Pten^tm1Rdp/Pten^tm1Rdp; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2

mortality/aging

premature death ( J:186105 )

• median survival time of 26.3 weeks

neoplasm

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

reproductive system

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:186105 )

♂ • all develop rapidly progressive, locally invasive prostate adenocarcinomas

increased prostate intraepithelial neoplasia incidence ( J:186105 )

♂ • high-grade prostate intraepithelial neoplasia (HPIN) in all mice by 9 weeks of age

Genotype
MGI:6694954

cn25

• Allelic Composition: Eaf1^tm1.1Zhow/Eaf1^tm1.1Zhow; Eaf2^tm1Zhow/Eaf2^tm1Zhow; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:288972 )

♂ • mouse prostatic intraepithelial neoplasia (mPIN) lesions

abnormal prostate gland physiology ( J:288972 )

♂ • increased epithelial cell proliferation in ventral prostate

prostate gland inflammation ( J:288972 )

♂ • stroma inflammation

♂ • increased CD3+ T cell and CD19+ B cell infiltration of ventral prostate

immune system

prostate gland inflammation ( J:288972 )

♂ • stroma inflammation

♂ • increased CD3+ T cell and CD19+ B cell infiltration of ventral prostate

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:288972 )

♂ • mouse prostatic intraepithelial neoplasia (mPIN) lesions

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:288972 )

♂ • mouse prostatic intraepithelial neoplasia (mPIN) lesions

abnormal prostate gland physiology ( J:288972 )

♂ • increased epithelial cell proliferation in ventral prostate

prostate gland inflammation ( J:288972 )

♂ • stroma inflammation

♂ • increased CD3+ T cell and CD19+ B cell infiltration of ventral prostate

Genotype
MGI:4819194

cn26

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Brn/Trp53⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

High-grade prostate intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0 Trp53^tm1Brn/Trp53^tm1Brn and prostate hyperplasia and intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53⁺ Tg(Pbsn-cre)4Prb/0 mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen at 10 - 14 months of age

♂ • by 15 - 20 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • levels of cell proliferation are 9 fold higher in PIN lesions

reproductive system

abnormal prostate gland morphology ( J:161511 )

♂ • focal hyperplasia is seen beginning at 10 -14 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen at 10 - 14 months of age

♂ • by 15 - 20 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • levels of cell proliferation are 9 fold higher in PIN lesions

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 4 fold increase in apoptotic cells in PIN foci

endocrine/exocrine glands

abnormal prostate gland morphology ( J:161511 )

♂ • focal hyperplasia is seen beginning at 10 -14 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen at 10 - 14 months of age

♂ • by 15 - 20 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • levels of cell proliferation are 9 fold higher in PIN lesions

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 4 fold increase in apoptotic cells in PIN foci

Genotype
MGI:4819193

cn27

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

High-grade prostate intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0 Trp53^tm1Brn/Trp53^tm1Brn and prostate hyperplasia and intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Trp53^tm1Brn/Trp53⁺ Tg(Pbsn-cre)4Prb/0 mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • by 10 - 14 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • frequently multiple ducts of each lobe have high grade PIN, which are present in proximal and distal regions of the prostate and consist of many atypical cells filling the lumen

♂ • high grade PIN lesions are predominantly seen in the anterior and dorsal prostate

♂ • levels of cell proliferation are 30 fold higher in PIN lesions

♂ • high grade PIN lesions frequently contain large groups of basal cells some of which are rounder in shape and positioned near the lumen

♂ • high grade lesions continue to proliferate post castration

reproductive system

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia is seen beginning as early as 6 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • by 10 - 14 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • frequently multiple ducts of each lobe have high grade PIN, which are present in proximal and distal regions of the prostate and consist of many atypical cells filling the lumen

♂ • high grade PIN lesions are predominantly seen in the anterior and dorsal prostate

♂ • levels of cell proliferation are 30 fold higher in PIN lesions

♂ • high grade PIN lesions frequently contain large groups of basal cells some of which are rounder in shape and positioned near the lumen

♂ • high grade lesions continue to proliferate post castration

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 20 fold increase in apoptotic cells in areas of high grade PIN

endocrine/exocrine glands

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia is seen beginning as early as 6 months of age

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • by 10 - 14 months of age both focal low grade and high grade PIN are seen

♂ • the incidence of high grade PIN is increased in mutant mice homozygous for the Trp53 allele relative to mice heterozygous for the Trp53 allele

♂ • frequently multiple ducts of each lobe have high grade PIN, which are present in proximal and distal regions of the prostate and consist of many atypical cells filling the lumen

♂ • high grade PIN lesions are predominantly seen in the anterior and dorsal prostate

♂ • levels of cell proliferation are 30 fold higher in PIN lesions

♂ • high grade PIN lesions frequently contain large groups of basal cells some of which are rounder in shape and positioned near the lumen

♂ • high grade lesions continue to proliferate post castration

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 20 fold increase in apoptotic cells in areas of high grade PIN

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:161511

Genotype
MGI:4819192

cn28

• Allelic Composition: Brca2^tm1Brn/Brca2^tm1Brn; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

Prostate hyperplasia and low-grade prostate intraepithelial neoplasia in Brca2^tm1Brn/Brca2^tm1Brn Tg(Pbsn-cre)4Prb/0 mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen in the lumen at 15 - 20 months of age

♂ • low grade PIN lesions form characteristic tufting and cribiform patterns

♂ • hyperplasia and low grade PIN are seen all 4 lobes

reproductive system

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia containing atypical cells is seen beginning at 10 -14 months of age

♂ • hyperplasia and low grade PIN are seen all 4 lobes

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen in the lumen at 15 - 20 months of age

♂ • low grade PIN lesions form characteristic tufting and cribiform patterns

♂ • hyperplasia and low grade PIN are seen all 4 lobes

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 3 fold increase in apoptotic cells in areas of hyperplasia and low grade PIN

endocrine/exocrine glands

prostate gland hyperplasia ( J:161511 )

♂ • focal hyperplasia containing atypical cells is seen beginning at 10 -14 months of age

♂ • hyperplasia and low grade PIN are seen all 4 lobes

increased prostate intraepithelial neoplasia incidence ( J:161511 )

♂ • focal low grade PIN are seen in the lumen at 15 - 20 months of age

♂ • low grade PIN lesions form characteristic tufting and cribiform patterns

♂ • hyperplasia and low grade PIN are seen all 4 lobes

abnormal prostate gland physiology ( J:161511 )

♂ • areas of hyperplasia are positive for markers of DNA damage

♂ • 3 fold increase in apoptotic cells in areas of hyperplasia and low grade PIN

Genotype
MGI:5427498

cn29

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺; Pten^tm1Mro/Pten⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N

Prostate cancer progression in Tg(Pbsn-cre)4Prb/0 Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺, Tg(Pbsn-cre)4Prb/0 Pten^tm1Mro/Pten⁺, and Tg(Pbsn-cre)4Prb/0 Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺ Pten^tm1Mro/Pten⁺ mice

neoplasm

increased prostate gland adenocarcinoma incidence ( J:184533 )

♂ • 55% penetrance at 1 year

♂ • multifocal, predominantly localized in the dorsolateral lobe that are locally invasive and highly vascularized

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • at 6 months

renal/urinary system

urinary bladder obstruction ( J:184533 )

• frequently

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:184533 )

♂ • 55% penetrance at 1 year

♂ • multifocal, predominantly localized in the dorsolateral lobe that are locally invasive and highly vascularized

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • at 6 months

reproductive system

increased prostate gland adenocarcinoma incidence ( J:184533 )

♂ • 55% penetrance at 1 year

♂ • multifocal, predominantly localized in the dorsolateral lobe that are locally invasive and highly vascularized

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • at 6 months

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:184533

Genotype
MGI:5427497

cn30

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N

Prostate cancer progression in Tg(Pbsn-cre)4Prb/0 Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺, Tg(Pbsn-cre)4Prb/0 Pten^tm1Mro/Pten⁺, and Tg(Pbsn-cre)4Prb/0 Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺ Pten^tm1Mro/Pten⁺ mice

reproductive system

prostate gland hyperplasia ( J:184533 )

♂ • at 6 months, mice exhibit atypical hyperplastic foci in the prostate lobes unlike control mice

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • multifocal lesions at 9 months

neoplasm

neoplasm ( J:184533 )

N • mice do not develop adenocarcinomas

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • multifocal lesions at 9 months

endocrine/exocrine glands

prostate gland hyperplasia ( J:184533 )

♂ • at 6 months, mice exhibit atypical hyperplastic foci in the prostate lobes unlike control mice

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • multifocal lesions at 9 months

Genotype
MGI:5705651

cn31

• Allelic Composition: Col1a1^{tm1(tetO-YAP1*)Fcam}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA,EGFP)Nagy}/Gt(ROSA)26Sor⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2

neoplasm

increased prostate gland tumor incidence ( J:222916 )

♂ • 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age

♂ • tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

increased prostate gland adenocarcinoma incidence ( J:222916 )

♂

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:222916 )

♂ • 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age

♂ • tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

increased prostate gland adenocarcinoma incidence ( J:222916 )

♂

reproductive system

increased prostate gland tumor incidence ( J:222916 )

♂ • 4 of 11 mice administered doxycycline at 3 months of age develop prostate tumors with age

♂ • tumors include adenocarcinomas, sarcomatoid carcinomas (epithelial-mesenchymal transition-like epithelial tumor), and stromal-type tumors

increased prostate gland adenocarcinoma incidence ( J:222916 )

♂

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:222916

Genotype
MGI:5009703

cn32

• Allelic Composition: Ar^tm1Verh/Y; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2

neoplasm

increased prostate gland adenocarcinoma incidence ( J:172730 )

♂ • mutants develop adenocarcinoma in the dorsolateral lobes of the prostate

♂ • cancer progression is similar to single conditional Pten mice

♂ • proliferation and apoptotic indexes are increased in the cancers, most notably in the proximal regions of the dorsal-lateral lobe

♂ • mutant tumors contain low or no p63+ cells, similar to human prostate cancer

♂ • castrated mutants develop cancer outgrowths in the dorsolateral lobes, indicating that mutants develop castrate-resistant prostate cancer

♂ • castrated mice treated with rapamycin show a reduction in prostate volume and reduced prostate proliferation

reproductive system

increased prostate gland adenocarcinoma incidence ( J:172730 )

♂ • mutants develop adenocarcinoma in the dorsolateral lobes of the prostate

♂ • cancer progression is similar to single conditional Pten mice

♂ • proliferation and apoptotic indexes are increased in the cancers, most notably in the proximal regions of the dorsal-lateral lobe

♂ • mutant tumors contain low or no p63+ cells, similar to human prostate cancer

♂ • castrated mutants develop cancer outgrowths in the dorsolateral lobes, indicating that mutants develop castrate-resistant prostate cancer

♂ • castrated mice treated with rapamycin show a reduction in prostate volume and reduced prostate proliferation

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:172730 )

♂ • mutants develop adenocarcinoma in the dorsolateral lobes of the prostate

♂ • cancer progression is similar to single conditional Pten mice

♂ • proliferation and apoptotic indexes are increased in the cancers, most notably in the proximal regions of the dorsal-lateral lobe

♂ • mutant tumors contain low or no p63+ cells, similar to human prostate cancer

♂ • castrated mutants develop cancer outgrowths in the dorsolateral lobes, indicating that mutants develop castrate-resistant prostate cancer

♂ • castrated mice treated with rapamycin show a reduction in prostate volume and reduced prostate proliferation

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:172730

Genotype
MGI:3836577

cn33

• Allelic Composition: Kras^tm1Bbd/Kras⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2

reproductive system

prostate gland hyperplasia ( J:143034 )

♂ • at 200 days, 100% of mice exhibit atypical hyperplasia unlike wild-type mice

♂ • at 500 days, 93% of mice exhibit atypical hyperplasia unlike wild-type mice

increased prostate gland adenocarcinoma incidence ( J:143034 )

♂ • in 7% of mice at 500 days

increased prostate intraepithelial neoplasia incidence ( J:143034 )

♂ • at 200 days, 67% of mice develop prostate intraepithelial neoplasia that display foci of small solid and cribiform intraluminal proliferation of atypical cells and nuclear atypia unlike wild-type mice

♂ • at 500 days, 60% of mice exhibit prostate intraepithelial neoplasia unlike in wild-type mice

neoplasm

increased prostate gland adenocarcinoma incidence ( J:143034 )

♂ • in 7% of mice at 500 days

increased prostate intraepithelial neoplasia incidence ( J:143034 )

♂ • at 200 days, 67% of mice develop prostate intraepithelial neoplasia that display foci of small solid and cribiform intraluminal proliferation of atypical cells and nuclear atypia unlike wild-type mice

♂ • at 500 days, 60% of mice exhibit prostate intraepithelial neoplasia unlike in wild-type mice

endocrine/exocrine glands

prostate gland hyperplasia ( J:143034 )

♂ • at 200 days, 100% of mice exhibit atypical hyperplasia unlike wild-type mice

♂ • at 500 days, 93% of mice exhibit atypical hyperplasia unlike wild-type mice

increased prostate gland adenocarcinoma incidence ( J:143034 )

♂ • in 7% of mice at 500 days

increased prostate intraepithelial neoplasia incidence ( J:143034 )

♂ • at 200 days, 67% of mice develop prostate intraepithelial neoplasia that display foci of small solid and cribiform intraluminal proliferation of atypical cells and nuclear atypia unlike wild-type mice

♂ • at 500 days, 60% of mice exhibit prostate intraepithelial neoplasia unlike in wild-type mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:143034

Genotype
MGI:6378625

cn34

• Allelic Composition: Gt(ROSA)26Sor^{tm1(CAG-PTPN1,-EGFP)Mtr}/Gt(ROSA)26Sor⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2

endocrine/exocrine glands

prostate gland anterior lobe hyperplasia ( J:231906 )

♂ • mice show a moderate incidence of epithelial hyperplasia in the anterior prostate

increased prostate intraepithelial neoplasia incidence ( J:231906 )

♂ • one mouse shows a prostatic intraepithelial neoplasia (mPIN) in the dorsolateral prostate

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:231906 )

♂ • one mouse shows a prostatic intraepithelial neoplasia (mPIN) in the dorsolateral prostate

reproductive system

prostate gland anterior lobe hyperplasia ( J:231906 )

♂ • mice show a moderate incidence of epithelial hyperplasia in the anterior prostate

increased prostate intraepithelial neoplasia incidence ( J:231906 )

♂ • one mouse shows a prostatic intraepithelial neoplasia (mPIN) in the dorsolateral prostate

Genotype
MGI:4830313

cn35

• Allelic Composition: Eif4e^tm1.1Lfur/Eif4e^tm1.1Lfur; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2

neoplasm

decreased tumor incidence ( J:163589 )

• at 7 months, mice exhibit fewer incidence of high grade prostate intraepithelial neoplasia due to delayed onset and decreased cell proliferation compared with Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

• mice do not exhibit infiltrating adenocarcinoma in the prostate unlike Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

Genotype
MGI:3836578

cn36

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Kras^tm1Bbd/Kras⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2

mortality/aging

premature death ( J:143034 )

• mice die prior to day 300

reproductive system

squamous metaplasia of bulbourethral gland ( J:143034 )

♂ • mice exhibit keratinized squamous metaplasia in the bulbourethral gland unlike wild-type mice

increased prostate gland tumor incidence ( J:143034 )

♂ • all mice develop diffuse, locally invasive carcinomas in the prostate that develop from solid or sheet-like proliferation with occasional rosette structures, nuclear atypia, apoptotic bodies, and mitosis unlike in wild-type mice

neoplasm

increased prostate gland tumor incidence ( J:143034 )

♂ • all mice develop diffuse, locally invasive carcinomas in the prostate that develop from solid or sheet-like proliferation with occasional rosette structures, nuclear atypia, apoptotic bodies, and mitosis unlike in wild-type mice

renal/urinary system

squamous metaplasia of urethral gland ( J:143034 )

• mice exhibit keratinized squamous metaplasia in the urethral gland unlike wild-type mice

endocrine/exocrine glands

squamous metaplasia of bulbourethral gland ( J:143034 )

♂ • mice exhibit keratinized squamous metaplasia in the bulbourethral gland unlike wild-type mice

increased prostate gland tumor incidence ( J:143034 )

♂ • all mice develop diffuse, locally invasive carcinomas in the prostate that develop from solid or sheet-like proliferation with occasional rosette structures, nuclear atypia, apoptotic bodies, and mitosis unlike in wild-type mice

squamous metaplasia of urethral gland ( J:143034 )

• mice exhibit keratinized squamous metaplasia in the urethral gland unlike wild-type mice

Genotype
MGI:6507888

cn37

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Igs2^{tm1(CAG-Met)Zsu}/Igs2⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:284956 )

♂ • mice develop aggressive adenocarcinomas that occur with much higher frequency than in single Ctnnb1^tm1Mmt conditional mutants, developing prostatic invasive adenocarcinomas as early as 7 months of age

♂ • 4 of 4 mice show intracystic adenocarcinoma at 6-9 months of age, with 1 of 4 mice showing invasive adenocarcinoma

♂ • 13 of 13 mice show intracystic adenocarcinoma at 9 months or older, with 5 of 13 showing invasive adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:284956 )

♂ • mice develop PIN lesions starting at 4-6 weeks of age, with 5 of 5 mice showing high grade PIN before 6 months of age

♂ • mice develop more severe PIN lesions and faster disease progression than single Ctnnb1^tm1Mmt conditional mutants

♂ • lesions in the anterior, dorsal, and lateral prostate lobes are more severe than in the ventral prostate

♂ • typical cribriform and papilliferous structures completely fill the lumen of prostatic glands

neoplasm

increased prostate gland adenocarcinoma incidence ( J:284956 )

♂ • mice develop aggressive adenocarcinomas that occur with much higher frequency than in single Ctnnb1^tm1Mmt conditional mutants, developing prostatic invasive adenocarcinomas as early as 7 months of age

♂ • 4 of 4 mice show intracystic adenocarcinoma at 6-9 months of age, with 1 of 4 mice showing invasive adenocarcinoma

♂ • 13 of 13 mice show intracystic adenocarcinoma at 9 months or older, with 5 of 13 showing invasive adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:284956 )

♂ • mice develop PIN lesions starting at 4-6 weeks of age, with 5 of 5 mice showing high grade PIN before 6 months of age

♂ • mice develop more severe PIN lesions and faster disease progression than single Ctnnb1^tm1Mmt conditional mutants

♂ • lesions in the anterior, dorsal, and lateral prostate lobes are more severe than in the ventral prostate

♂ • typical cribriform and papilliferous structures completely fill the lumen of prostatic glands

reproductive system

increased prostate gland adenocarcinoma incidence ( J:284956 )

♂ • mice develop aggressive adenocarcinomas that occur with much higher frequency than in single Ctnnb1^tm1Mmt conditional mutants, developing prostatic invasive adenocarcinomas as early as 7 months of age

♂ • 4 of 4 mice show intracystic adenocarcinoma at 6-9 months of age, with 1 of 4 mice showing invasive adenocarcinoma

♂ • 13 of 13 mice show intracystic adenocarcinoma at 9 months or older, with 5 of 13 showing invasive adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:284956 )

♂ • mice develop PIN lesions starting at 4-6 weeks of age, with 5 of 5 mice showing high grade PIN before 6 months of age

♂ • mice develop more severe PIN lesions and faster disease progression than single Ctnnb1^tm1Mmt conditional mutants

♂ • lesions in the anterior, dorsal, and lateral prostate lobes are more severe than in the ventral prostate

♂ • typical cribriform and papilliferous structures completely fill the lumen of prostatic glands

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:284956

Genotype
MGI:6507865

cn38

• Allelic Composition: Igs2^{tm1(CAG-Met)Zsu}/Igs2⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:268934 )

N • mice do not show any obvious pathological changes in prostate tissues from birth to 20 months of age

increased prostate intraepithelial neoplasia incidence ( J:268934 )

• mice administered recombinant human hepatocyte growth factor at 6 months of age show lesions of typical low-grade prostatic intraepithelial neoplasia not seen in hepatocyte growth factor-administered wild-type mice

• however, hepatocyte growth factor-administered mice do not develop prostate carcinomas

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:268934 )

• mice administered recombinant human hepatocyte growth factor at 6 months of age show lesions of typical low-grade prostatic intraepithelial neoplasia not seen in hepatocyte growth factor-administered wild-type mice

• however, hepatocyte growth factor-administered mice do not develop prostate carcinomas

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:268934 )

• mice administered recombinant human hepatocyte growth factor at 6 months of age show lesions of typical low-grade prostatic intraepithelial neoplasia not seen in hepatocyte growth factor-administered wild-type mice

• however, hepatocyte growth factor-administered mice do not develop prostate carcinomas

Genotype
MGI:6275174

cn39

• Allelic Composition: Gt(ROSA)26Sor^{tm1(SPOP*F133V)Mrbn}/Gt(ROSA)26Sor⁺; Pten^tm2.1Ppp/Pten⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * DBA/2

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:239660 )

♂ • 1 of 5 mice older than 12 months exhibit areas of invasive prostate carcinoma

increased prostate intraepithelial neoplasia incidence ( J:239660 )

♂ • mice exhibit a high penetrance of focal areas of high-grade prostatic intraepithelial neoplasia by 6 months of age, characterized by nuclear atypia

neoplasm

increased prostate gland adenocarcinoma incidence ( J:239660 )

♂ • 1 of 5 mice older than 12 months exhibit areas of invasive prostate carcinoma

increased prostate intraepithelial neoplasia incidence ( J:239660 )

♂ • mice exhibit a high penetrance of focal areas of high-grade prostatic intraepithelial neoplasia by 6 months of age, characterized by nuclear atypia

reproductive system

increased prostate gland adenocarcinoma incidence ( J:239660 )

♂ • 1 of 5 mice older than 12 months exhibit areas of invasive prostate carcinoma

increased prostate intraepithelial neoplasia incidence ( J:239660 )

♂ • mice exhibit a high penetrance of focal areas of high-grade prostatic intraepithelial neoplasia by 6 months of age, characterized by nuclear atypia

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:239660

Genotype
MGI:3603330

cn40

• Allelic Composition: Pten^tm2.1Ppp/Pten^tm2.1Ppp; Trp53^tm1Thl/Trp53^tm1Thl; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * DBA/2

mortality/aging

premature death ( J:100683 )

• all mutants died by 7 months of age

neoplasm

increased prostate gland tumor incidence ( J:100683 )

♂ • invasive prostatic cancer is seen in all mutants by 10 weeks of age

♂ • average tumor weight is increased 32-fold compared to mutants wild-type for Trp53 and these tumors encompass the entire genitourinary tract and pelvis

♂ • no increase is seen in the number of senescent cells compared to wild-type prostates unlike in mutants wild-type for Trp53

increased carcinoma incidence ( J:100683 )

• by 11 weeks of age invasive adenocarcinoma develops

renal/urinary system

urinary bladder obstruction ( J:100683 )

• bladder obstruction

kidney failure ( J:100683 )

reproductive system

increased prostate gland tumor incidence ( J:100683 )

♂ • invasive prostatic cancer is seen in all mutants by 10 weeks of age

♂ • average tumor weight is increased 32-fold compared to mutants wild-type for Trp53 and these tumors encompass the entire genitourinary tract and pelvis

♂ • no increase is seen in the number of senescent cells compared to wild-type prostates unlike in mutants wild-type for Trp53

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:100683 )

♂ • invasive prostatic cancer is seen in all mutants by 10 weeks of age

♂ • average tumor weight is increased 32-fold compared to mutants wild-type for Trp53 and these tumors encompass the entire genitourinary tract and pelvis

♂ • no increase is seen in the number of senescent cells compared to wild-type prostates unlike in mutants wild-type for Trp53

Genotype
MGI:2679901

cn41

• Allelic Composition: Pten^tm2.1Ppp/Pten^tm2.1Ppp; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * DBA/2

reproductive system

abnormal prostate gland morphology ( J:86212 )

♂ • large, irregular cells, occasionally forming cryptic glandular structures

abnormal prostate gland epithelium morphology ( J:86212 )

♂ • prostate epithelial dysplasia

prostate gland epithelial hyperplasia ( J:86212 , J:100683 )

♂ • focal areas of epithelial hyperplasia (J:86212)

♂ • increased proliferation of epithelial cells (J:86212)

♂ • mutant prostates contain a 20-fold increase in senescent epithelial cells compared to wild-type prostates (J:100683)

enlarged prostate gland ( J:86212 )

♂ • massive enlargement of all prostatic lobes evident at 2 to 3 months of age, complete penetrance

prostate gland hyperplasia ( J:86212 )

♂

increased prostate gland tumor incidence ( J:86212 , J:100683 )

♂ • tumors were undifferentiated and often affected multiple lobes, suggesting multifocal origns (J:86212)

♂ • complete penetrance of invasive and diffuse prostate cancer with disruption of basement membrane and signs of organ infiltration (J:86212)

♂ • invasive prostatic cancer develops after a 4-6 month latency; however none of the mutants had died of prostatic cancer by 10 months of age (J:100683)

♂ • tumors retain clearly defined urogenital organ boundaries (J:100683)

increased prostate gland adenocarcinoma incidence ( J:100683 , J:163589 )

♂ (J:100683)

♂ (J:163589)

increased prostate intraepithelial neoplasia incidence ( J:100683 , J:163589 , J:200002 , J:239660 )

♂ • high-grade prostatic intraepithelial neoplasia are seen in all 3 prostatic lobes in 9-week old mutants (J:100683)

♂ (J:163589)

♂ • that does not progress to grossly invasive disease (J:200002)

♂ • mice develop diffuse, highly proliferative high-grade prostatic intraepithelial neoplasia without invasive cancer but with cystic enlargement of the anterior prostate (J:239660)

neoplasm

increased prostate gland tumor incidence ( J:86212 , J:100683 )

♂ • tumors were undifferentiated and often affected multiple lobes, suggesting multifocal origns (J:86212)

♂ • complete penetrance of invasive and diffuse prostate cancer with disruption of basement membrane and signs of organ infiltration (J:86212)

♂ • invasive prostatic cancer develops after a 4-6 month latency; however none of the mutants had died of prostatic cancer by 10 months of age (J:100683)

♂ • tumors retain clearly defined urogenital organ boundaries (J:100683)

increased prostate gland adenocarcinoma incidence ( J:100683 , J:163589 )

♂ (J:100683)

♂ (J:163589)

increased prostate intraepithelial neoplasia incidence ( J:100683 , J:163589 , J:200002 , J:239660 )

♂ • high-grade prostatic intraepithelial neoplasia are seen in all 3 prostatic lobes in 9-week old mutants (J:100683)

♂ (J:163589)

♂ • that does not progress to grossly invasive disease (J:200002)

♂ • mice develop diffuse, highly proliferative high-grade prostatic intraepithelial neoplasia without invasive cancer but with cystic enlargement of the anterior prostate (J:239660)

endocrine/exocrine glands

abnormal prostate gland morphology ( J:86212 )

♂ • large, irregular cells, occasionally forming cryptic glandular structures

abnormal prostate gland epithelium morphology ( J:86212 )

♂ • prostate epithelial dysplasia

prostate gland epithelial hyperplasia ( J:86212 , J:100683 )

♂ • focal areas of epithelial hyperplasia (J:86212)

♂ • increased proliferation of epithelial cells (J:86212)

♂ • mutant prostates contain a 20-fold increase in senescent epithelial cells compared to wild-type prostates (J:100683)

enlarged prostate gland ( J:86212 )

♂ • massive enlargement of all prostatic lobes evident at 2 to 3 months of age, complete penetrance

prostate gland hyperplasia ( J:86212 )

♂

increased prostate gland tumor incidence ( J:86212 , J:100683 )

♂ • tumors were undifferentiated and often affected multiple lobes, suggesting multifocal origns (J:86212)

♂ • complete penetrance of invasive and diffuse prostate cancer with disruption of basement membrane and signs of organ infiltration (J:86212)

♂ • invasive prostatic cancer develops after a 4-6 month latency; however none of the mutants had died of prostatic cancer by 10 months of age (J:100683)

♂ • tumors retain clearly defined urogenital organ boundaries (J:100683)

increased prostate gland adenocarcinoma incidence ( J:100683 , J:163589 )

♂ (J:100683)

♂ (J:163589)

increased prostate intraepithelial neoplasia incidence ( J:100683 , J:163589 , J:200002 , J:239660 )

♂ • high-grade prostatic intraepithelial neoplasia are seen in all 3 prostatic lobes in 9-week old mutants (J:100683)

♂ (J:163589)

♂ • that does not progress to grossly invasive disease (J:200002)

♂ • mice develop diffuse, highly proliferative high-grade prostatic intraepithelial neoplasia without invasive cancer but with cystic enlargement of the anterior prostate (J:239660)

Genotype
MGI:5524280

cn42

• Allelic Composition: Gt(ROSA)26Sor^{tm1(TMPRSS2/ERG)Key}/Gt(ROSA)26Sor^{tm1(TMPRSS2/ERG)Key}; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * DBA/2

mortality/aging

premature death ( J:200002 )

♂ • shortened survival compared with Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

reproductive system

enlarged prostate gland ( J:200002 )

♂ • enlarged and hardened by 6 months

increased prostate gland adenocarcinoma incidence ( J:200002 )

♂ • invasive with small irregular glandular structures composed of malignant cells with large, pleiomorphic nuclei and pale cytoplasm by 8 weeks

increased prostate intraepithelial neoplasia incidence ( J:200002 )

♂ • with a proliferative index only slightly higher than in Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

abnormal prostate gland physiology ( J:200002 )

♂ • proliferative index only slightly higher than in Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

penis prolapse ( J:200002 )

♂

neoplasm

increased prostate gland adenocarcinoma incidence ( J:200002 )

♂ • invasive with small irregular glandular structures composed of malignant cells with large, pleiomorphic nuclei and pale cytoplasm by 8 weeks

increased prostate intraepithelial neoplasia incidence ( J:200002 )

♂ • with a proliferative index only slightly higher than in Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

renal/urinary system

penis prolapse ( J:200002 )

♂

growth/size/body

distended abdomen ( J:200002 )

♂ • increased abdominal girth

endocrine/exocrine glands

enlarged prostate gland ( J:200002 )

♂ • enlarged and hardened by 6 months

increased prostate gland adenocarcinoma incidence ( J:200002 )

♂ • invasive with small irregular glandular structures composed of malignant cells with large, pleiomorphic nuclei and pale cytoplasm by 8 weeks

increased prostate intraepithelial neoplasia incidence ( J:200002 )

♂ • with a proliferative index only slightly higher than in Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

abnormal prostate gland physiology ( J:200002 )

♂ • proliferative index only slightly higher than in Pten^tm2.1Ppp/Pten^tm2.1Ppp Tg(Pbsn-cre)4Prb mice

Genotype
MGI:6275175

cn43

• Allelic Composition: Gt(ROSA)26Sor^{tm1(SPOP*F133V)Mrbn}/Gt(ROSA)26Sor⁺; Pten^tm2.1Ppp/Pten^tm2.1Ppp; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * DBA/2

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:239660 )

♂ • mice exhibit severely enlarged prostates with areas of solid tumor by 12 months of age

♂ • 80% of mice display invasive, poorly differentiated carcinomas; tumors are highly proliferative with transitional sarcomatoid differentiation and maintain expression of androgen receptor

neoplasm

increased prostate gland adenocarcinoma incidence ( J:239660 )

♂ • mice exhibit severely enlarged prostates with areas of solid tumor by 12 months of age

♂ • 80% of mice display invasive, poorly differentiated carcinomas; tumors are highly proliferative with transitional sarcomatoid differentiation and maintain expression of androgen receptor

reproductive system

increased prostate gland adenocarcinoma incidence ( J:239660 )

♂ • mice exhibit severely enlarged prostates with areas of solid tumor by 12 months of age

♂ • 80% of mice display invasive, poorly differentiated carcinomas; tumors are highly proliferative with transitional sarcomatoid differentiation and maintain expression of androgen receptor

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:239660

Genotype
MGI:6198768

cn44

• Allelic Composition: Eif2ak3^tm1.2Drc/Eif2ak3^tm1.2Drc; Pten^tm1Hwu/Pten^tm1Hwu; Tg(CAG-MYC,-GFP*)#Rugg/0; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2

endocrine/exocrine glands

decreased prostate gland tumor incidence ( J:261540 )

♂ • mice show reduced prostate growth, with a decrease prostate cancer progression and cell proliferation compared to Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0 Tg(CAG-MYC,-GFP)#Rugg/0 mice

neoplasm

decreased prostate gland tumor incidence ( J:261540 )

♂ • mice show reduced prostate growth, with a decrease prostate cancer progression and cell proliferation compared to Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0 Tg(CAG-MYC,-GFP)#Rugg/0 mice

reproductive system

decreased prostate gland tumor incidence ( J:261540 )

♂ • mice show reduced prostate growth, with a decrease prostate cancer progression and cell proliferation compared to Pten^tm1Hwu/Pten^tm1Hwu Tg(Pbsn-cre)4Prb/0 Tg(CAG-MYC,-GFP)#Rugg/0 mice

Genotype
MGI:4420974

cn45

• Allelic Composition: Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2

mortality/aging

premature death ( J:93902 )

• 3 of 14 mice die by age 12 to 29 weeks

• however, all castrated mice survive from 7 to 10 months

decreased tumor-free survival time ( J:124208 )

• 12 month survival rate of mutants is 60% on the high-omega-3 diet, 10% on the low-omega-3 diet and 0% on the high-omega-6 diet

• mutants on a high-omega-6 diet do not survive beyond 10 months of age and die due to bladder obstruction by the prostate tumor compressing the urethra

reproductive system

abnormal prostate gland morphology ( J:124208 )

♂ • prostate lobes are enlarged and exhibit increased vascularity and cellularity

abnormal prostate gland epithelium morphology ( J:93902 )

♂ • at 4 weeks, epithelium cells in the lateral prostate are larger than in Pten^tm1Hwu homozygotes

prostate gland epithelial hyperplasia ( J:93902 )

♂ • without cellular atypia by 4 weeks of age

enlarged prostate gland ( J:93902 )

♂ • mice exhibit progressive enlargement of the prostate gland compared to in Pten^tm1Hwu homozygotes

♂ • however, castration reduces prostate size

increased prostate gland weight ( J:124208 )

♂ • prostate weight is higher than in controls starting at 8 weeks of age

♂ • prostate weight gain from 5 to 24 weeks is significantly less in mice fed a high-omega-3 diet than in mice fed a high-omega-6 diet

prostate gland hyperplasia ( J:93902 )

♂ • at 4 weeks, mice develop multifocal hyperplasia compared to in Pten^tm1Hwu homozygotes

♂ • hyperplasia is initially observed in the dorsolateral and ventral lobe with subsequent involvement of the anterior lobes

increased prostate gland tumor incidence ( J:124208 )

♂ • males develop prostate cancer

increased prostate gland adenocarcinoma incidence ( J:93902 , J:124208 )

♂ • mice develop invasive adenocarcinoma by 9 weeks of age in all lobes (J:93902)

♂ • prostate cancers are metastatic (J:93902)

♂ • castrated mice still develop invasive adenocarcinoma (J:93902)

♂ • 80% of mutants fed a high-omega-6 diet develop invasive carcinoma while 50% of mutants fed a high-omega-3 diet develop invasive carcinoma (J:124208)

increased prostate intraepithelial neoplasia incidence ( J:93902 , J:106650 )

♂ • by 6 weeks of age, all mice develop prostate intraepithelial neoplasia (J:93902)

♂ • latency to prostate intraepithelial neoplasia is 1.5 months (J:93902)

♂ • males develop PIN lesions after 16 months of age (J:106650)

abnormal prostate gland physiology ( J:93902 , J:124208 )

♂ • prostate cancer cells exhibit increased proliferation compared to in Pten^tm1Hwu homozygotes (J:93902)

♂ • cancer cells induce a desmoplastic response (J:93902)

♂ • castrated mice exhibit increased proliferation compared with similarly treated Pten^tm1Hwu homozygotes (J:93902)

♂ • higher numbers of apoptotic cells are seen in mutant prostates from mice on the high-omega-3 diet than on the high-omega-6 diet (J:124208)

prostate gland inflammation ( J:93902 )

♂ • cancer cells induce inflammation

neoplasm

increased prostate gland tumor incidence ( J:124208 )

♂ • males develop prostate cancer

increased prostate gland adenocarcinoma incidence ( J:93902 , J:124208 )

♂ • prostate cancers are metastatic (J:93902)

♂ • castrated mice still develop invasive adenocarcinoma (J:93902)

♂ • mice develop invasive adenocarcinoma by 9 weeks of age in all lobes (J:93902)

♂ • 80% of mutants fed a high-omega-6 diet develop invasive carcinoma while 50% of mutants fed a high-omega-3 diet develop invasive carcinoma (J:124208)

increased prostate intraepithelial neoplasia incidence ( J:93902 , J:106650 )

♂ • by 6 weeks of age, all mice develop prostate intraepithelial neoplasia (J:93902)

♂ • latency to prostate intraepithelial neoplasia is 1.5 months (J:93902)

♂ • males develop PIN lesions after 16 months of age (J:106650)

decreased tumor incidence ( J:124208 )

• omega-3 polyunsaturated fatty acids (PUFAs) slow the progression of prostate tumors in 5- to 8-week old mutants; once carcinoma develops, omega-3 PUFAs induce apoptosis and decrease the growth of the tumor

immune system

prostate gland inflammation ( J:93902 )

♂ • cancer cells induce inflammation

pyelonephritis ( J:124208 )

• mutants surviving 6 months or longer exhibit pyelonephritis

endocrine/exocrine glands

abnormal prostate gland morphology ( J:124208 )

♂ • prostate lobes are enlarged and exhibit increased vascularity and cellularity

abnormal prostate gland epithelium morphology ( J:93902 )

♂ • at 4 weeks, epithelium cells in the lateral prostate are larger than in Pten^tm1Hwu homozygotes

prostate gland epithelial hyperplasia ( J:93902 )

♂ • without cellular atypia by 4 weeks of age

enlarged prostate gland ( J:93902 )

♂ • mice exhibit progressive enlargement of the prostate gland compared to in Pten^tm1Hwu homozygotes

♂ • however, castration reduces prostate size

increased prostate gland weight ( J:124208 )

♂ • prostate weight is higher than in controls starting at 8 weeks of age

♂ • prostate weight gain from 5 to 24 weeks is significantly less in mice fed a high-omega-3 diet than in mice fed a high-omega-6 diet

prostate gland hyperplasia ( J:93902 )

♂ • at 4 weeks, mice develop multifocal hyperplasia compared to in Pten^tm1Hwu homozygotes

♂ • hyperplasia is initially observed in the dorsolateral and ventral lobe with subsequent involvement of the anterior lobes

increased prostate gland tumor incidence ( J:124208 )

♂ • males develop prostate cancer

increased prostate gland adenocarcinoma incidence ( J:93902 , J:124208 )

♂ • mice develop invasive adenocarcinoma by 9 weeks of age in all lobes (J:93902)

♂ • prostate cancers are metastatic (J:93902)

♂ • castrated mice still develop invasive adenocarcinoma (J:93902)

♂ • 80% of mutants fed a high-omega-6 diet develop invasive carcinoma while 50% of mutants fed a high-omega-3 diet develop invasive carcinoma (J:124208)

increased prostate intraepithelial neoplasia incidence ( J:93902 , J:106650 )

♂ • by 6 weeks of age, all mice develop prostate intraepithelial neoplasia (J:93902)

♂ • latency to prostate intraepithelial neoplasia is 1.5 months (J:93902)

♂ • males develop PIN lesions after 16 months of age (J:106650)

abnormal prostate gland physiology ( J:93902 , J:124208 )

♂ • prostate cancer cells exhibit increased proliferation compared to in Pten^tm1Hwu homozygotes (J:93902)

♂ • cancer cells induce a desmoplastic response (J:93902)

♂ • castrated mice exhibit increased proliferation compared with similarly treated Pten^tm1Hwu homozygotes (J:93902)

♂ • higher numbers of apoptotic cells are seen in mutant prostates from mice on the high-omega-3 diet than on the high-omega-6 diet (J:124208)

prostate gland inflammation ( J:93902 )

♂ • cancer cells induce inflammation

renal/urinary system

abnormal renal/urinary system physiology ( J:124208 )

• mutants surviving 6 months or longer exhibit retention of urine in the anterior prostate lobes

pyelonephritis ( J:124208 )

• mutants surviving 6 months or longer exhibit pyelonephritis

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:93902

Genotype
MGI:4847617

cn46

• Allelic Composition: Pten^tm1Hwu/Pten^tm1Hwu; Tg(CAG-fat-1)1Jxk/0; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2

endocrine/exocrine glands

decreased prostate gland weight ( J:124208 )

♂ • mice fed a high-omega-6 diet exhibit significantly lower prostate weights than mice without Tg(CAG-fat-1)1Jxk

homeostasis/metabolism

abnormal lipid homeostasis ( J:124208 )

• mice fed a high-omega-6 diet exhibit a much lower omega-6/omega-3 ratio in the blood and prostate than mice without the Tg(CAG-fat-1)1Jxk transgene, indicating that fat-1 is able to convert most of the omega-6 polyunsaturated fatty acids to omega-3

reproductive system

decreased prostate gland weight ( J:124208 )

♂ • mice fed a high-omega-6 diet exhibit significantly lower prostate weights than mice without Tg(CAG-fat-1)1Jxk

Genotype
MGI:4843916

cn47

• Allelic Composition: Pten^tm1Hwu/Pten⁺; Tg(ARR2/Pbsn-FGF8)3Prb/0; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2

endocrine/exocrine glands

prostate gland epithelial hyperplasia ( J:106650 )

♂

enlarged prostate gland ( J:106650 )

♂ • enlarged prostate gland due to epithelial hyperplasia

increased prostate gland adenocarcinoma incidence ( J:106650 )

♂ • prostatic adenocarcinomas are seen from 9 months onward

♂ • adenocarcinomas are seen in all lobes, although more often in the dorsolateral and ventral lobes than anterior lobes

♂ • 6 of 17 mutants at 9-16.2 months of age and 9 of 10 mutants at 18.2-19.1 months exhibit adenocarcinomas

♂ • adenocarcinomas show loss of heterozygosity of Pten

♂ • 2 of 31 mutants develop a rare form of mucinous adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:106650 )

♂ • males by 6.5 months of age exhibit hyperplasia and focal-low grade PIN lesions in the prostate

♂ • males older than 7.5 months of age exhibit high-grade PINs

reproductive system

prostate gland epithelial hyperplasia ( J:106650 )

♂

enlarged prostate gland ( J:106650 )

♂ • enlarged prostate gland due to epithelial hyperplasia

increased prostate gland adenocarcinoma incidence ( J:106650 )

♂ • prostatic adenocarcinomas are seen from 9 months onward

♂ • adenocarcinomas are seen in all lobes, although more often in the dorsolateral and ventral lobes than anterior lobes

♂ • 6 of 17 mutants at 9-16.2 months of age and 9 of 10 mutants at 18.2-19.1 months exhibit adenocarcinomas

♂ • adenocarcinomas show loss of heterozygosity of Pten

♂ • 2 of 31 mutants develop a rare form of mucinous adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:106650 )

♂ • males by 6.5 months of age exhibit hyperplasia and focal-low grade PIN lesions in the prostate

♂ • males older than 7.5 months of age exhibit high-grade PINs

neoplasm

increased prostate gland adenocarcinoma incidence ( J:106650 )

♂ • prostatic adenocarcinomas are seen from 9 months onward

♂ • adenocarcinomas are seen in all lobes, although more often in the dorsolateral and ventral lobes than anterior lobes

♂ • 6 of 17 mutants at 9-16.2 months of age and 9 of 10 mutants at 18.2-19.1 months exhibit adenocarcinomas

♂ • adenocarcinomas show loss of heterozygosity of Pten

♂ • 2 of 31 mutants develop a rare form of mucinous adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:106650 )

♂ • males by 6.5 months of age exhibit hyperplasia and focal-low grade PIN lesions in the prostate

♂ • males older than 7.5 months of age exhibit high-grade PINs

increased metastatic potential ( J:106650 )

• metastasis of adenocarcionma into lymph nodes is observed, with 50-60% penetrance

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:106650

Genotype
MGI:4420975

cn48

• Allelic Composition: Pten^tm1Hwu/Pten⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:93902 )

♂ • latency to prostate intraepithelial neoplasia is 8 to 10 months

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:93902 )

♂ • latency to prostate intraepithelial neoplasia is 8 to 10 months

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:93902 )

♂ • latency to prostate intraepithelial neoplasia is 8 to 10 months

Genotype
MGI:6198766

cn49

• Allelic Composition: Pten^tm1Hwu/Pten^tm1Hwu; Tg(CAG-MYC,-GFP*)#Rugg/0; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2

mortality/aging

premature death ( J:261540 )

♂ • mice show decreased overall survival, with a mean life span of 75 weeks

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:261540 )

♂ • mice develop prostatic adenocarcinoma by 10 weeks of age

♂ • mice with developed tumors treated with a small-molecule inhibitor of P-eIF2alpha activity, ISRIB, show tumor regression within 3 weeks of treatment, with no signs of toxicity

increased prostate intraepithelial neoplasia incidence ( J:261540 )

♂ • mice show enlargement of prostate growth by 6 weeks of age and accelerated development of high-grade prostatic intraepithelial neoplasia compared to single conditional Pten^tm1Hwu mutants

neoplasm

increased prostate gland adenocarcinoma incidence ( J:261540 )

♂ • mice develop prostatic adenocarcinoma by 10 weeks of age

♂ • mice with developed tumors treated with a small-molecule inhibitor of P-eIF2alpha activity, ISRIB, show tumor regression within 3 weeks of treatment, with no signs of toxicity

increased prostate intraepithelial neoplasia incidence ( J:261540 )

♂ • mice show enlargement of prostate growth by 6 weeks of age and accelerated development of high-grade prostatic intraepithelial neoplasia compared to single conditional Pten^tm1Hwu mutants

reproductive system

increased prostate gland adenocarcinoma incidence ( J:261540 )

♂ • mice develop prostatic adenocarcinoma by 10 weeks of age

♂ • mice with developed tumors treated with a small-molecule inhibitor of P-eIF2alpha activity, ISRIB, show tumor regression within 3 weeks of treatment, with no signs of toxicity

increased prostate intraepithelial neoplasia incidence ( J:261540 )

♂ • mice show enlargement of prostate growth by 6 weeks of age and accelerated development of high-grade prostatic intraepithelial neoplasia compared to single conditional Pten^tm1Hwu mutants

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:261540

Genotype
MGI:5566610

cn50

• Allelic Composition: Apc^tm1Tno/Apc^tm1Tno; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2

mortality/aging

premature death ( J:120308 )

♂ • most mice die by 15 months of age

neoplasm

increased tumor incidence ( J:120308 )

♂ • a few mice develop unidentified tumors in the scrotal region, not obviously associated with the testes; these tumors are cystic and epithelial in origin

increased prostate gland adenocarcinoma incidence ( J:120308 )

♂ • all prostate lobes exhibit neoplasia with hyperplasia, multiple foci of squamous metaplasia and keratinization, and a prominent stromal reaction, including edema, inflammatory reaction and stromal hyperplasia by 7 months of age indicating adenocarcinoma

♂ • the anterior prostate shows the most severe phenotype, followed by the dorsal-lateral and then ventral prostate

♂ • small foci of tumor invasion into the stroma is seen but this is not common

♂ • mice castrated at 6 weeks show regions of hyperplasia, and squamous metaplasia at 32 weeks later, but not carcinoma, indicating inhibition of tumor formation

♂ • mice castrated after tumors still exhibit carcinoma 2 months postcastration

increased prostate intraepithelial neoplasia incidence ( J:120308 )

♂ • mice develop prostatic epithelial hyperplasia and prostatic intraepithelial neoplasia (PIN) as early as 4.5 to 7 weeks of age

endocrine/exocrine glands

prostate gland epithelial hyperplasia ( J:120308 )

♂ • mice develop prostatic epithelial hyperplasia as early as 4.5 to 7 weeks of age

increased prostate gland adenocarcinoma incidence ( J:120308 )

♂ • all prostate lobes exhibit neoplasia with hyperplasia, multiple foci of squamous metaplasia and keratinization, and a prominent stromal reaction, including edema, inflammatory reaction and stromal hyperplasia by 7 months of age indicating adenocarcinoma

♂ • the anterior prostate shows the most severe phenotype, followed by the dorsal-lateral and then ventral prostate

♂ • small foci of tumor invasion into the stroma is seen but this is not common

♂ • mice castrated at 6 weeks show regions of hyperplasia, and squamous metaplasia at 32 weeks later, but not carcinoma, indicating inhibition of tumor formation

♂ • mice castrated after tumors still exhibit carcinoma 2 months postcastration

increased prostate intraepithelial neoplasia incidence ( J:120308 )

♂ • mice develop prostatic epithelial hyperplasia and prostatic intraepithelial neoplasia (PIN) as early as 4.5 to 7 weeks of age

reproductive system

prostate gland epithelial hyperplasia ( J:120308 )

♂ • mice develop prostatic epithelial hyperplasia as early as 4.5 to 7 weeks of age

increased prostate gland adenocarcinoma incidence ( J:120308 )

♂ • all prostate lobes exhibit neoplasia with hyperplasia, multiple foci of squamous metaplasia and keratinization, and a prominent stromal reaction, including edema, inflammatory reaction and stromal hyperplasia by 7 months of age indicating adenocarcinoma

♂ • the anterior prostate shows the most severe phenotype, followed by the dorsal-lateral and then ventral prostate

♂ • small foci of tumor invasion into the stroma is seen but this is not common

♂ • mice castrated at 6 weeks show regions of hyperplasia, and squamous metaplasia at 32 weeks later, but not carcinoma, indicating inhibition of tumor formation

♂ • mice castrated after tumors still exhibit carcinoma 2 months postcastration

increased prostate intraepithelial neoplasia incidence ( J:120308 )

♂ • mice develop prostatic epithelial hyperplasia and prostatic intraepithelial neoplasia (PIN) as early as 4.5 to 7 weeks of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:120308

Genotype
MGI:5578649

cn51

• Allelic Composition: Pten^tm1Hwu/Pten⁺; Tmprss2^{tm2.1(ETV1)Sho}/Tmprss2^{tm2.1(ETV1)Sho}; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

mortality/aging

premature death ( J:212219 )

♂ • most mice die before 1 year of age

reproductive system

increased prostate gland adenocarcinoma incidence ( J:212219 )

♂ • invasive with metastasis into the prostate stroma and urogenital area

prostate gland cyst ( J:212219 )

♂ • large

neoplasm

increased prostate gland adenocarcinoma incidence ( J:212219 )

♂ • invasive with metastasis into the prostate stroma and urogenital area

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:212219 )

♂ • invasive with metastasis into the prostate stroma and urogenital area

prostate gland cyst ( J:212219 )

♂ • large

growth/size/body

prostate gland cyst ( J:212219 )

♂ • large

Genotype
MGI:5578652

cn52

• Allelic Composition: Erg^tm1.1Sho/Erg^tm1.1Sho; Pten^tm1Hwu/Pten^tm1Hwu; Tmprss2^tm3Sho/Tmprss2^tm3Sho; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:212219 )

♂ • regions of invasive prostate adenocarcinoma in mice over 1 year of age

mortality/aging

mortality/aging ( J:212219 )

♂N • mice survive at least 1 year

neoplasm

increased prostate gland adenocarcinoma incidence ( J:212219 )

♂ • regions of invasive prostate adenocarcinoma in mice over 1 year of age

reproductive system

increased prostate gland adenocarcinoma incidence ( J:212219 )

♂ • regions of invasive prostate adenocarcinoma in mice over 1 year of age

Genotype
MGI:2449982

cn53

• Allelic Composition: Rxra^tm1Krc/Rxra⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

reproductive system

abnormal prostate gland branching morphogenesis ( J:78553 )

♂ • branching morphogenesis of the prostate ductal system is increased 54% and 52% in the lateral prostate and anterior prostate, respectively

prostate gland epithelial hyperplasia ( J:78553 )

♂ • prostate hyperplasia after 11 months of age

increased prostate intraepithelial neoplasia incidence ( J:78553 )

♂ • low grade prostatic intraepithelial neoplasia after 14 months of age

♂ • after 18 months of age, some animals progress to high grade prostatic intraepithelial neoplasia

endocrine/exocrine glands

abnormal prostate gland branching morphogenesis ( J:78553 )

♂ • branching morphogenesis of the prostate ductal system is increased 54% and 52% in the lateral prostate and anterior prostate, respectively

prostate gland epithelial hyperplasia ( J:78553 )

♂ • prostate hyperplasia after 11 months of age

increased prostate intraepithelial neoplasia incidence ( J:78553 )

♂ • low grade prostatic intraepithelial neoplasia after 14 months of age

♂ • after 18 months of age, some animals progress to high grade prostatic intraepithelial neoplasia

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:78553 )

♂ • low grade prostatic intraepithelial neoplasia after 14 months of age

♂ • after 18 months of age, some animals progress to high grade prostatic intraepithelial neoplasia

Genotype
MGI:5705328

cn54

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Pten^tm1Hwu/Pten⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

mortality/aging

premature death ( J:184935 )

♂ • lethality around 40 weeks of age

neoplasm

increased prostate gland adenocarcinoma incidence ( J:184935 )

♂ • mice develop focal neoplastic expansions in the prostate by 10 weeks and invasive carcinoma by 20 weeks

increased metastatic potential ( J:184935 )

♂ • mice develop macrometastatic lesions in the lung and liver with 100% penetrance

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:184935 )

♂ • mice develop focal neoplastic expansions in the prostate by 10 weeks and invasive carcinoma by 20 weeks

reproductive system

increased prostate gland adenocarcinoma incidence ( J:184935 )

♂ • mice develop focal neoplastic expansions in the prostate by 10 weeks and invasive carcinoma by 20 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:184935

Genotype
MGI:5705321

cn55

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

neoplasm

increased prostate gland adenocarcinoma incidence ( J:184935 )

♂ • mice develop invasive carcinoma in both the dorsolateral and anterior lobes of the prostate as early as 4 weeks with poorly differentiated carcinoma by 10 weeks

♂ • marker analysis indicates that prostatic epithelial cells undergo epithelial-to-mesenchymal transition and that tumors exhibit a human metastatic prostate cancer signature

increased metastatic potential ( J:184935 )

♂ • mice develop macrometastatic lesions in the lung and liver with 100% penetrance

mortality/aging

premature death ( J:184935 )

♂ • early lethality, with mice dying between around 10 and 30 weeks of age

endocrine/exocrine glands

abnormal prostate gland morphology ( J:184935 )

♂ • prostates show an expansion of the leukemia stem cell (LSC)^high subpopulation of stem/progenitor cells

♂ • both the LSC^high (basal cell population) and LSC^low (luminal cell population) subpopulations show enhanced sphere-forming in vitro

increased prostate gland adenocarcinoma incidence ( J:184935 )

♂ • mice develop invasive carcinoma in both the dorsolateral and anterior lobes of the prostate as early as 4 weeks with poorly differentiated carcinoma by 10 weeks

♂ • marker analysis indicates that prostatic epithelial cells undergo epithelial-to-mesenchymal transition and that tumors exhibit a human metastatic prostate cancer signature

reproductive system

abnormal prostate gland morphology ( J:184935 )

♂ • prostates show an expansion of the leukemia stem cell (LSC)^high subpopulation of stem/progenitor cells

♂ • both the LSC^high (basal cell population) and LSC^low (luminal cell population) subpopulations show enhanced sphere-forming in vitro

increased prostate gland adenocarcinoma incidence ( J:184935 )

♂ • mice develop invasive carcinoma in both the dorsolateral and anterior lobes of the prostate as early as 4 weeks with poorly differentiated carcinoma by 10 weeks

♂ • marker analysis indicates that prostatic epithelial cells undergo epithelial-to-mesenchymal transition and that tumors exhibit a human metastatic prostate cancer signature

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:184935

Genotype
MGI:2449983

cn56

• Allelic Composition: Rxra^tm1Krc/Rxra^tm1Krc; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

reproductive system

abnormal prostate gland branching morphogenesis ( J:78553 )

♂ • branching morphogenesis of the prostate ductal system is increased 54% and 52% in the lateral prostate and anterior prostate, respectively

increased prostate intraepithelial neoplasia incidence ( J:78553 )

♂ • 71% incidence of prostatic intraepithelial neoplasia after 4 months of age

♂ • lesions progress to low grade prostatic intraepithelial neoplasia after 5 months of age

♂ • after 10 months of age, some animals progress to high grade prostatic intraepithelial neoplasia

abnormal prostate gland physiology ( J:78553 )

♂ • change in protein profile of secretory proteins

♂ • increase in prostatic cell proliferation rate

endocrine/exocrine glands

abnormal prostate gland branching morphogenesis ( J:78553 )

♂ • branching morphogenesis of the prostate ductal system is increased 54% and 52% in the lateral prostate and anterior prostate, respectively

increased prostate intraepithelial neoplasia incidence ( J:78553 )

♂ • 71% incidence of prostatic intraepithelial neoplasia after 4 months of age

♂ • lesions progress to low grade prostatic intraepithelial neoplasia after 5 months of age

♂ • after 10 months of age, some animals progress to high grade prostatic intraepithelial neoplasia

abnormal prostate gland physiology ( J:78553 )

♂ • change in protein profile of secretory proteins

♂ • increase in prostatic cell proliferation rate

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:78553 )

♂ • 71% incidence of prostatic intraepithelial neoplasia after 4 months of age

♂ • lesions progress to low grade prostatic intraepithelial neoplasia after 5 months of age

♂ • after 10 months of age, some animals progress to high grade prostatic intraepithelial neoplasia

Genotype
MGI:5008589

cn57

• Allelic Composition: Gt(ROSA)26Sor^{tm2(H1/tetO-RNAi:Pdpk1)Mrl}/Gt(ROSA)26Sor⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

reproductive system

enlarged prostate gland anterior lobe ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland weight ( J:170965 )

♂ • in doxycycline-treated mice

prostate gland hyperplasia ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland tumor incidence ( J:170965 )

♂ • doxycycline-treated mice exhibit microinvasive tumors in the prostate gland unlike in Pdpk1^tm1Dral homozygotes

neoplasm

increased prostate gland tumor incidence ( J:170965 )

♂ • doxycycline-treated mice exhibit microinvasive tumors in the prostate gland unlike in Pdpk1^tm1Dral homozygotes

endocrine/exocrine glands

enlarged prostate gland anterior lobe ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland weight ( J:170965 )

♂ • in doxycycline-treated mice

prostate gland hyperplasia ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland tumor incidence ( J:170965 )

♂ • doxycycline-treated mice exhibit microinvasive tumors in the prostate gland unlike in Pdpk1^tm1Dral homozygotes

Genotype
MGI:5008586

cn58

• Allelic Composition: Gt(ROSA)26Sor^{tm1(H1/tetO-RNAi:Pdpk1)Mrl}/Gt(ROSA)26Sor⁺; Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

reproductive system

enlarged prostate gland anterior lobe ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland weight ( J:170965 )

♂ • in doxycycline-treated mice

prostate gland hyperplasia ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland tumor incidence ( J:170965 )

♂ • doxycycline-treated mice exhibit microinvasive tumors in the prostate gland unlike in Pdk1^tm1Dral homozygotes

abnormal prostate gland physiology ( J:170965 )

♂ • doxycycline-treated mice exhibit increased proliferation in the prostate gland compared to in Pdk1^tm1Dral homozygotes

neoplasm

increased prostate gland tumor incidence ( J:170965 )

♂ • doxycycline-treated mice exhibit microinvasive tumors in the prostate gland unlike in Pdk1^tm1Dral homozygotes

endocrine/exocrine glands

enlarged prostate gland anterior lobe ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland weight ( J:170965 )

♂ • in doxycycline-treated mice

prostate gland hyperplasia ( J:170965 )

♂ • in doxycycline-treated mice

increased prostate gland tumor incidence ( J:170965 )

♂ • doxycycline-treated mice exhibit microinvasive tumors in the prostate gland unlike in Pdk1^tm1Dral homozygotes

abnormal prostate gland physiology ( J:170965 )

♂ • doxycycline-treated mice exhibit increased proliferation in the prostate gland compared to in Pdk1^tm1Dral homozygotes

Genotype
MGI:4358249

cn59

• Allelic Composition: Pten^tm1Hwu/Pten^tm1Hwu; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

mortality/aging

mortality/aging ( J:212219 )

♂N • mice survive at least 1 year

reproductive system

enlarged prostate gland anterior lobe ( J:170965 )

♂

increased prostate gland weight ( J:170965 )

♂

prostate gland hyperplasia ( J:170965 )

♂

increased prostate gland tumor incidence ( J:170965 , J:172730 , J:268934 )

♂ • mice exhibit microinvasive tumors in the prostate gland unlike in Pdpk1^tm1Dral homozygotes (J:170965)

♂ • mutants develop castrate-resistant prostate cancer (J:172730)

♂ • mice develop intracystic prostatic carcinomas between 4 and 10 months of age (J:268934)

increased prostate gland adenocarcinoma incidence ( J:184935 , J:212219 , J:268934 )

♂ • mice predominately develop adenocarcinoma localized to the dorsolateral lobes of the prostate (J:184935)

♂ • localized lesions that slowly progress to prostate adenocarcinomas (J:212219)

♂ • 4 of 8 mice develop prostatic adenocarcinoma and 3 of 8 mice exhibit invasive carcinomas after 10 months (J:268934)

increased prostate intraepithelial neoplasia incidence ( J:131932 , J:212219 , J:268934 )

♂ • in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 7 weeks (J:131932)

♂ • localized lesions that slowly progress to prostate adenocarcinomas (J:212219)

♂ • 4 of 4 mice develop low grade pancreatic intraepithelial neoplasia (PIN) and 2 of 4 mice show multifocal high grade PIN before 4 months of age (J:268934)

♂ • 6 of 6 mice exhibit multifocal high grade PIN at 4-10 months of age (J:268934)

neoplasm

increased prostate gland tumor incidence ( J:170965 , J:172730 , J:268934 )

♂ • mice exhibit microinvasive tumors in the prostate gland unlike in Pdpk1^tm1Dral homozygotes (J:170965)

♂ • mutants develop castrate-resistant prostate cancer (J:172730)

♂ • mice develop intracystic prostatic carcinomas between 4 and 10 months of age (J:268934)

increased prostate gland adenocarcinoma incidence ( J:184935 , J:212219 , J:268934 )

♂ • mice predominately develop adenocarcinoma localized to the dorsolateral lobes of the prostate (J:184935)

♂ • localized lesions that slowly progress to prostate adenocarcinomas (J:212219)

♂ • 4 of 8 mice develop prostatic adenocarcinoma and 3 of 8 mice exhibit invasive carcinomas after 10 months (J:268934)

increased prostate intraepithelial neoplasia incidence ( J:131932 , J:212219 , J:268934 )

♂ • in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 7 weeks (J:131932)

♂ • localized lesions that slowly progress to prostate adenocarcinomas (J:212219)

♂ • 4 of 4 mice develop low grade pancreatic intraepithelial neoplasia (PIN) and 2 of 4 mice show multifocal high grade PIN before 4 months of age (J:268934)

♂ • 6 of 6 mice exhibit multifocal high grade PIN at 4-10 months of age (J:268934)

increased metastatic potential ( J:268934 )

♂ • prostate cancer metastasis after 10 months of age, with 12.5% of mice showing metastatic lesions to lungs and lymph nodes

increased carcinoma incidence ( J:268934 )

♂ • 2 of 6 mice develop intracystic prostatic carcinomas between 4 and 10 months of age

♂ • 6 of 8 mice show intracystic prostatic carcinoma after 10 months of age

endocrine/exocrine glands

enlarged prostate gland anterior lobe ( J:170965 )

♂

increased prostate gland weight ( J:170965 )

♂

prostate gland hyperplasia ( J:170965 )

♂

increased prostate gland tumor incidence ( J:170965 , J:172730 , J:268934 )

♂ • mice exhibit microinvasive tumors in the prostate gland unlike in Pdpk1^tm1Dral homozygotes (J:170965)

♂ • mutants develop castrate-resistant prostate cancer (J:172730)

♂ • mice develop intracystic prostatic carcinomas between 4 and 10 months of age (J:268934)

increased prostate gland adenocarcinoma incidence ( J:184935 , J:212219 , J:268934 )

♂ • mice predominately develop adenocarcinoma localized to the dorsolateral lobes of the prostate (J:184935)

♂ • localized lesions that slowly progress to prostate adenocarcinomas (J:212219)

♂ • 4 of 8 mice develop prostatic adenocarcinoma and 3 of 8 mice exhibit invasive carcinomas after 10 months (J:268934)

increased prostate intraepithelial neoplasia incidence ( J:131932 , J:212219 , J:268934 )

♂ • in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 7 weeks (J:131932)

♂ • localized lesions that slowly progress to prostate adenocarcinomas (J:212219)

♂ • 4 of 4 mice develop low grade pancreatic intraepithelial neoplasia (PIN) and 2 of 4 mice show multifocal high grade PIN before 4 months of age (J:268934)

♂ • 6 of 6 mice exhibit multifocal high grade PIN at 4-10 months of age (J:268934)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:172730 , J:184935

Genotype
MGI:6378626

cn60

• Allelic Composition: Pten^tm1Hwu/Pten^tm1Hwu; Ptpn1^tm1Bpk/Ptpn1^tm1Bpk; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * DBA/2

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:231906 )

♂ • one mouse at 6 weeks of age shows a microinvasive adenocarcinoma

♂ • mice fed a high-fat diet upon weaning show an increase in the penetrance and number of microinvasive foci of microinvasive adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:231906 )

♂ • mice show a similar number of prostate ductules affected by intraepithelial neoplasia (mPIN) as single Pten^tm1Hwu conditional mice

neoplasm

increased prostate gland adenocarcinoma incidence ( J:231906 )

♂ • one mouse at 6 weeks of age shows a microinvasive adenocarcinoma

♂ • mice fed a high-fat diet upon weaning show an increase in the penetrance and number of microinvasive foci of microinvasive adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:231906 )

♂ • mice show a similar number of prostate ductules affected by intraepithelial neoplasia (mPIN) as single Pten^tm1Hwu conditional mice

reproductive system

increased prostate gland adenocarcinoma incidence ( J:231906 )

♂ • one mouse at 6 weeks of age shows a microinvasive adenocarcinoma

♂ • mice fed a high-fat diet upon weaning show an increase in the penetrance and number of microinvasive foci of microinvasive adenocarcinoma

increased prostate intraepithelial neoplasia incidence ( J:231906 )

♂ • mice show a similar number of prostate ductules affected by intraepithelial neoplasia (mPIN) as single Pten^tm1Hwu conditional mice

Genotype
MGI:5446522

cn61

• Allelic Composition: Zfhx3^tm1.1Jtd/Zfhx3^tm1.1Jtd; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:189563 )

• in mice with cre-expression in the prostate

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:189563 )

• in mice with cre-expression in the prostate

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:189563 )

• in mice with cre-expression in the prostate

Genotype
MGI:3773634

cn62

• Allelic Composition: Ar^tm1Chc/Y; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S/SvEv * C57BL/6 * DBA/2

reproductive system

reproductive system phenotype ( J:123402 )

♂N • anogenital distances and internal urogenital organs, with exception of prostate gland, show no differences from wild-type

♂N • no difference relative to wild-type in terms of fertility is observed

abnormal prostate gland morphology ( J:123402 )

♂ • at 9 weeks of age, some ventral prostate ducts lose glandular infoldings and have abnormal epithelial cells; enlarged ducts have many sloughed epithelial cells

♂ • by 14 weeks, glandular infoldings have become smaller and shorter, some with constriction at their base, and layers of sloughed epithelial cells are observed in prostate lumen; by 32 weeks, mutant tissue lacks glandular infolding

♂ • by week 24, layers of sloughed epithelium, immune cells and DNA fragments are observed in lumen of ducts in ventral prostate; many TUNEL-positive cells are detected in prostatic lumen at 24 weeks

abnormal prostate gland epithelium morphology ( J:123402 )

♂ • at 9 weeks of age, some ducts in the ventral prostate contain short or low cuboidal cells compared to taller or columnar epithelial cells in wild-type males; at 14 weeks, around 50% of ducts within the ventral prostate have altered epithelial architecture, with short poorly differentiated epithelial cells

♂ • at 14-32 weeks, epithelial cells are shrunken

♂ • by week 24, proliferation in the epithelium of all lobes except for anterior prostatic lobe is increased significantly compared to wild-type prostates

♂ • epithelial cells appear to undergo anoikis and detach from the basement membrane

enlarged prostate gland ventral lobe ( J:123402 )

♂ • at week 24, ventral prostates of mutants are substantially larger than in wild-type males

♂ • however, dorsal-lateral prostates and anterior prostates show no changes in size

endocrine/exocrine glands

abnormal prostate gland morphology ( J:123402 )

♂ • at 9 weeks of age, some ventral prostate ducts lose glandular infoldings and have abnormal epithelial cells; enlarged ducts have many sloughed epithelial cells

♂ • by 14 weeks, glandular infoldings have become smaller and shorter, some with constriction at their base, and layers of sloughed epithelial cells are observed in prostate lumen; by 32 weeks, mutant tissue lacks glandular infolding

♂ • by week 24, layers of sloughed epithelium, immune cells and DNA fragments are observed in lumen of ducts in ventral prostate; many TUNEL-positive cells are detected in prostatic lumen at 24 weeks

abnormal prostate gland epithelium morphology ( J:123402 )

♂ • at 9 weeks of age, some ducts in the ventral prostate contain short or low cuboidal cells compared to taller or columnar epithelial cells in wild-type males; at 14 weeks, around 50% of ducts within the ventral prostate have altered epithelial architecture, with short poorly differentiated epithelial cells

♂ • at 14-32 weeks, epithelial cells are shrunken

♂ • by week 24, proliferation in the epithelium of all lobes except for anterior prostatic lobe is increased significantly compared to wild-type prostates

♂ • epithelial cells appear to undergo anoikis and detach from the basement membrane

enlarged prostate gland ventral lobe ( J:123402 )

♂ • at week 24, ventral prostates of mutants are substantially larger than in wild-type males

♂ • however, dorsal-lateral prostates and anterior prostates show no changes in size

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:123402 )

♂N • serum testosterone levels at 12 and 24 weeks of age are similar to those in wild-type males

Genotype
MGI:3716207

cn63

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/?; Tg(Pbsn-cre)4Prb/?
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * DBA/2

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:114992 )

N • no increased hyperproliferative lesions or neoplastic transformation of the prostate are observed

Genotype
MGI:3836579

cn64

• Allelic Composition: Ctnnb1^tm1Mmt/Ctnnb1⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * DBA/2

mortality/aging

premature death ( J:143034 )

• at 428 days

reproductive system

squamous metaplasia of preputial gland ( J:143034 )

• keratinized squamous metaplasia of the preputial gland develops at 100 days (67% incidence), 200 days and at end-point (100% incidence)

squamous metaplasia of bulbourethral gland ( J:143034 )

♂ • mice exhibit keratinized squamous metaplasia in the bulbourethral gland with incidence of 67% at 100 days and 100% at 200 days unlike wild-type mice

increased prostate gland adenocarcinoma incidence ( J:143034 , J:284956 )

♂ • at 200 days, mice develop adenocarcinoma foci (J:143034)

♂ • at end-point, 100% of mice develop diffuse and locally invasive adenocarcinoma unlike wild-type mice (J:143034)

♂ • prostatic tumor tissues show changes consistent with prostatic intracystic adenocarcinomas (J:284956)

♂ • 3 of 5 mice show intracystic adenocarcinoma at 6-9 months of age (J:284956)

♂ • 9 of 12 mice show intracystic adenocarcinoma at 9 months or older, with 1 of 12 showing invasive adenocarcinoma (J:284956)

increased prostate intraepithelial neoplasia incidence ( J:143034 , J:284956 )

♂ • at 100 days, mice exhibit diffuse prostate intraepithelial neoplasia-like keratinized squamous metaplasia unlike in wild-type mice (J:143034)

♂ • at 200 days, mice exhibit high-grade prostate intraepithelial neoplasia-like keratinized squamous metaplasia unlike in wild-type mice (J:143034)

♂ • mice develop PIN lesions starting at 4-6 weeks of age (J:284956)

♂ • 4 of 4 mice develop low grade PIN before 6 months of age and 3 of 4 mice show high grade PIN before 6 months of age (J:284956)

♂ • 5 of 5 mice develop high grade PIN at 6-9 months of age (J:284956)

neoplasm

increased prostate gland adenocarcinoma incidence ( J:143034 , J:284956 )

♂ • at 200 days, mice develop adenocarcinoma foci (J:143034)

♂ • at end-point, 100% of mice develop diffuse and locally invasive adenocarcinoma unlike wild-type mice (J:143034)

♂ • prostatic tumor tissues show changes consistent with prostatic intracystic adenocarcinomas (J:284956)

♂ • 3 of 5 mice show intracystic adenocarcinoma at 6-9 months of age (J:284956)

♂ • 9 of 12 mice show intracystic adenocarcinoma at 9 months or older, with 1 of 12 showing invasive adenocarcinoma (J:284956)

increased prostate intraepithelial neoplasia incidence ( J:143034 , J:284956 )

♂ • at 100 days, mice exhibit diffuse prostate intraepithelial neoplasia-like keratinized squamous metaplasia unlike in wild-type mice (J:143034)

♂ • at 200 days, mice exhibit high-grade prostate intraepithelial neoplasia-like keratinized squamous metaplasia unlike in wild-type mice (J:143034)

♂ • mice develop PIN lesions starting at 4-6 weeks of age (J:284956)

♂ • 4 of 4 mice develop low grade PIN before 6 months of age and 3 of 4 mice show high grade PIN before 6 months of age (J:284956)

♂ • 5 of 5 mice develop high grade PIN at 6-9 months of age (J:284956)

renal/urinary system

squamous metaplasia of urethral gland ( J:143034 )

• urethral keratinized squamous metaplasia develops in 17% at day 200 and 28% at end-points unlike in wild-type mice

endocrine/exocrine glands

squamous metaplasia of preputial gland ( J:143034 )

• keratinized squamous metaplasia of the preputial gland develops at 100 days (67% incidence), 200 days and at end-point (100% incidence)

squamous metaplasia of bulbourethral gland ( J:143034 )

♂ • mice exhibit keratinized squamous metaplasia in the bulbourethral gland with incidence of 67% at 100 days and 100% at 200 days unlike wild-type mice

increased prostate gland adenocarcinoma incidence ( J:143034 , J:284956 )

♂ • at 200 days, mice develop adenocarcinoma foci (J:143034)

♂ • at end-point, 100% of mice develop diffuse and locally invasive adenocarcinoma unlike wild-type mice (J:143034)

♂ • prostatic tumor tissues show changes consistent with prostatic intracystic adenocarcinomas (J:284956)

♂ • 3 of 5 mice show intracystic adenocarcinoma at 6-9 months of age (J:284956)

♂ • 9 of 12 mice show intracystic adenocarcinoma at 9 months or older, with 1 of 12 showing invasive adenocarcinoma (J:284956)

increased prostate intraepithelial neoplasia incidence ( J:143034 , J:284956 )

♂ • at 100 days, mice exhibit diffuse prostate intraepithelial neoplasia-like keratinized squamous metaplasia unlike in wild-type mice (J:143034)

♂ • at 200 days, mice exhibit high-grade prostate intraepithelial neoplasia-like keratinized squamous metaplasia unlike in wild-type mice (J:143034)

♂ • mice develop PIN lesions starting at 4-6 weeks of age (J:284956)

♂ • 4 of 4 mice develop low grade PIN before 6 months of age and 3 of 4 mice show high grade PIN before 6 months of age (J:284956)

♂ • 5 of 5 mice develop high grade PIN at 6-9 months of age (J:284956)

squamous metaplasia of urethral gland ( J:143034 )

• urethral keratinized squamous metaplasia develops in 17% at day 200 and 28% at end-points unlike in wild-type mice

integument

squamous metaplasia of preputial gland ( J:143034 )

• keratinized squamous metaplasia of the preputial gland develops at 100 days (67% incidence), 200 days and at end-point (100% incidence)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:143034

Genotype
MGI:6198765

cn65

• Allelic Composition: Tg(CAG-MYC,-GFP*)#Rugg/0; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: C57BL/6 * C57BL/6J * DBA/2

endocrine/exocrine glands

abnormal prostate gland morphology ( J:261540 )

♂ • mice exhibit increased proliferation in the prostate epithelium but do not develop adenocarcinoma by 1 year of age

neoplasm

neoplasm ( J:261540 )

♂N • mice do not develop prostate gland adenocarcinoma by 1 year of age

reproductive system

abnormal prostate gland morphology ( J:261540 )

♂ • mice exhibit increased proliferation in the prostate epithelium but do not develop adenocarcinoma by 1 year of age

Genotype
MGI:5551716

cn66

• Allelic Composition: Klf5^tm1.1Jtd/Klf5⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: C57BL/6 * DBA/2

Abnormal prostate morphology in Klf5^tm1.1Jtd/Klf5⁺ Tg(Pbsn-cre)4Prb/0 and Klf5^tm1.1Jtd/Klf5^tm1.1Jtd Tg(Pbsn-cre)4Prb/0 males

reproductive system

abnormal prostate gland anterior lobe morphology ( J:206639 )

• thick cell layers

abnormal prostate gland dorsolateral lobe morphology ( J:206639 )

• thick cell layers

decreased prostate gland weight ( J:206639 )

• increased castration-induced shrinkage of the prostate

• however, administration of androgen restores weight

prostate gland hyperplasia ( J:206639 )

• more severe than in Klf5^tm1.1Jtd/Klf5^tm1.1Jtd Tg(Pbsn-cre)4Prb mice

abnormal prostate gland physiology ( J:206639 )

• increased cell proliferation compared to in Klf5^tm1.1Jtd/Klf5^tm1.1Jtd Tg(Pbsn-cre)4Prb mice and mice with wild-type alleles

neoplasm

neoplasm ( J:206639 )

N • at 1 and 2 years, mice do not develop increased incidence of prostatic intraepithelial neoplasia

endocrine/exocrine glands

abnormal prostate gland anterior lobe morphology ( J:206639 )

• thick cell layers

abnormal prostate gland dorsolateral lobe morphology ( J:206639 )

• thick cell layers

decreased prostate gland weight ( J:206639 )

• increased castration-induced shrinkage of the prostate

• however, administration of androgen restores weight

prostate gland hyperplasia ( J:206639 )

• more severe than in Klf5^tm1.1Jtd/Klf5^tm1.1Jtd Tg(Pbsn-cre)4Prb mice

abnormal prostate gland physiology ( J:206639 )

• increased cell proliferation compared to in Klf5^tm1.1Jtd/Klf5^tm1.1Jtd Tg(Pbsn-cre)4Prb mice and mice with wild-type alleles

Genotype
MGI:5551715

cn67

• Allelic Composition: Klf5^tm1.1Jtd/Klf5^tm1.1Jtd; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: C57BL/6 * DBA/2

Abnormal prostate morphology in Klf5^tm1.1Jtd/Klf5⁺ Tg(Pbsn-cre)4Prb/0 and Klf5^tm1.1Jtd/Klf5^tm1.1Jtd Tg(Pbsn-cre)4Prb/0 males

reproductive system

decreased prostate gland weight ( J:206639 )

• increased castration-induced shrinkage of the prostate

• however, administration of androgen restores weight

prostate gland hyperplasia ( J:206639 )

• benign

abnormal prostate gland physiology ( J:206639 )

• increased cell apoptosis compared to in Klf5^tm1.1Jtd/Klf5⁺ Tg(Pbsn-cre)4Prb mice and mice with wild-type alleles

neoplasm

neoplasm ( J:206639 )

N • at 1 and 2 years, mice do not develop increased incidence of prostatic intraepithelial neoplasia

endocrine/exocrine glands

decreased prostate gland weight ( J:206639 )

• increased castration-induced shrinkage of the prostate

• however, administration of androgen restores weight

prostate gland hyperplasia ( J:206639 )

• benign

abnormal prostate gland physiology ( J:206639 )

• increased cell apoptosis compared to in Klf5^tm1.1Jtd/Klf5⁺ Tg(Pbsn-cre)4Prb mice and mice with wild-type alleles

Genotype
MGI:6114993

cn68

• Allelic Composition: Tg(CAG-cat,-ALOX15)1868Klv/0; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: C57BL/6 * DBA/2

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:114903 )

♂ • dorsolateral and ventral prostates show age-dependent focal and progressive epithelial hyperplasia with atypia which shows increased proliferation indicating high grade prostatic intraepithelial neoplasia after 5 months of age

♂ • micropapillary projections of mildly atypical epithelium are seen in distal dorsal prostate lumens and nuclei show mild enlargement, including elongation and hyperchromasia

♂ • lateral prostate shows progressively severe nuclear stratification, with nuclear atypia with some enlargement and hyperchromasia with chromatin clumping

♂ • however, no progression to invasive prostate cancer was seen up to 35 weeks

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:114903 )

♂ • dorsolateral and ventral prostates show age-dependent focal and progressive epithelial hyperplasia with atypia which shows increased proliferation indicating high grade prostatic intraepithelial neoplasia after 5 months of age

♂ • micropapillary projections of mildly atypical epithelium are seen in distal dorsal prostate lumens and nuclei show mild enlargement, including elongation and hyperchromasia

♂ • lateral prostate shows progressively severe nuclear stratification, with nuclear atypia with some enlargement and hyperchromasia with chromatin clumping

♂ • however, no progression to invasive prostate cancer was seen up to 35 weeks

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:114903 )

♂ • dorsolateral and ventral prostates show age-dependent focal and progressive epithelial hyperplasia with atypia which shows increased proliferation indicating high grade prostatic intraepithelial neoplasia after 5 months of age

♂ • micropapillary projections of mildly atypical epithelium are seen in distal dorsal prostate lumens and nuclei show mild enlargement, including elongation and hyperchromasia

♂ • lateral prostate shows progressively severe nuclear stratification, with nuclear atypia with some enlargement and hyperchromasia with chromatin clumping

♂ • however, no progression to invasive prostate cancer was seen up to 35 weeks

Genotype
MGI:6114995

cn69

• Allelic Composition: Tg(CAG-cat,-ALOX15)1868Klv/Tg(CAG-cat,-ALOX15)1868Klv; Tg(Pbsn-cre)4Prb/?
• Genetic Background: involves: C57BL/6 * DBA/2

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:114903 )

♂ • dorsolateral and ventral prostates show age-dependent focal and progressive epithelial hyperplasia with atypia which shows increased proliferation indicating high grade prostatic intraepithelial neoplasia after 5 months of age

♂ • micropapillary projections of mildly atypical epithelium are seen in distal dorsal prostate lumens and nuclei show mild enlargement, including elongation and hyperchromasia

♂ • lateral prostate shows progressively severe nuclear stratification, with nuclear atypia with some enlargement and hyperchromasia with chromatin clumping

♂ • however, no progression to invasive prostate cancer was seen up to 35 weeks

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:114903 )

♂ • dorsolateral and ventral prostates show age-dependent focal and progressive epithelial hyperplasia with atypia which shows increased proliferation indicating high grade prostatic intraepithelial neoplasia after 5 months of age

♂ • micropapillary projections of mildly atypical epithelium are seen in distal dorsal prostate lumens and nuclei show mild enlargement, including elongation and hyperchromasia

♂ • lateral prostate shows progressively severe nuclear stratification, with nuclear atypia with some enlargement and hyperchromasia with chromatin clumping

♂ • however, no progression to invasive prostate cancer was seen up to 35 weeks

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:114903 )

♂ • dorsolateral and ventral prostates show age-dependent focal and progressive epithelial hyperplasia with atypia which shows increased proliferation indicating high grade prostatic intraepithelial neoplasia after 5 months of age

♂ • micropapillary projections of mildly atypical epithelium are seen in distal dorsal prostate lumens and nuclei show mild enlargement, including elongation and hyperchromasia

♂ • lateral prostate shows progressively severe nuclear stratification, with nuclear atypia with some enlargement and hyperchromasia with chromatin clumping

♂ • however, no progression to invasive prostate cancer was seen up to 35 weeks

Genotype
MGI:5427499

cn70

• Allelic Composition: Pten^tm1Mro/Pten⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: C57BL/6 * DBA/2

Prostate cancer progression in Tg(Pbsn-cre)4Prb/0 Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺, Tg(Pbsn-cre)4Prb/0 Pten^tm1Mro/Pten⁺, and Tg(Pbsn-cre)4Prb/0 Gt(ROSA)26Sor^{tm1(CAG-Bmi1,-EGFP)Nki}/Gt(ROSA)26Sor⁺ Pten^tm1Mro/Pten⁺ mice

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • in 40% of mice at 9 months

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • in 40% of mice at 9 months

endocrine/exocrine glands

increased prostate intraepithelial neoplasia incidence ( J:184533 )

♂ • in 40% of mice at 9 months

Genotype
MGI:6275172

cn71

• Allelic Composition: Gt(ROSA)26Sor^{tm1(SPOP*F133V)Mrbn}/Gt(ROSA)26Sor⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: C57BL/6 * DBA/2

endocrine/exocrine glands

abnormal prostate gland morphology ( J:239660 )

♂ • rare areas in prostate show outlier levels of androgen receptor expression and rare cells show cytologic atypia with enlarged nuclei in mice older than 12 months

♂ • however, mice show minimal alterations in prostate grandular architecture and histology, no differences in proliferation or androgen receptor expression

reproductive system

abnormal prostate gland morphology ( J:239660 )

♂ • rare areas in prostate show outlier levels of androgen receptor expression and rare cells show cytologic atypia with enlarged nuclei in mice older than 12 months

♂ • however, mice show minimal alterations in prostate grandular architecture and histology, no differences in proliferation or androgen receptor expression

Genotype
MGI:3603329

cn72

• Allelic Composition: Trp53^tm1Thl/Trp53^tm1Thl; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: C57BL/6 * DBA/2

neoplasm

neoplasm ( J:100683 )

N • no prostatic tumors are detected in 9-week old mutants